

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 November 2001 (22.11.2001)

PCT

(10) International Publication Number
WO 01/87929 A2

(51) International Patent Classification⁷: **C07K 14/00**

(21) International Application Number: **PCT/EP01/05559**

(22) International Filing Date: **16 May 2001 (16.05.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/205,195 **18 May 2000 (18.05.2000)** **US**

(71) Applicant (for all designated States except US): **BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE).**

(72) Inventor; and

(75) Inventor/Applicant (for US only): **RAMAKRISHNAN, Shyam [IN/US]; 76 Euston Road, Apt. #10, Brighton, MA 02135 (US).**

(74) Common Representative: **BAYER AKTIENGESELLSCHAFT; 51368 Leverkusen (DE).**

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**

(84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **REGULATION OF HUMAN DOPAMINE-LIKE G PROTEIN-COUPLED RECEPTOR**

(57) Abstract: Reagents which regulate human dopamine-like G protein-coupled receptor (DA-like GPCR) and reagents which bind to human DA-like GPCR gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, obesity and diseases related to obesity, cancer, diabetes, osteoporosis, anxiety, depression, hypertension, migraine, compulsive disorders, schizophrenia, autism, neurodegenerative disorders, such as Alzheimer's disease, Parkinsonism, and Huntington's chorea, and cancer chemotherapy-induced vomiting.

WO 01/87929 A2

REGULATION OF HUMAN DOPAMINE-LIKE G PROTEIN-COUPLED RECEPTOR

5 TECHNICAL FIELD OF THE INVENTION

The invention relates to the area of G-protein coupled receptors. More particularly, it relates to the area of human dopamine-like G protein-coupled receptor and its regulation.

10

BACKGROUND OF THE INVENTION

G-Protein Coupled Receptors

15 Many medically significant biological processes are mediated by signal transduction pathways that involve G-proteins (Lefkowitz, *Nature* 351, 353-354, 1991). The family of G-protein coupled receptors (GPCR) includes receptors for hormones, neurotransmitters, growth factors, and viruses. Specific examples of GPCRs include receptors for such diverse agents as calcitonin, adrenergic hormones, endothelin, cAMP, adenosine, acetylcholine, serotonin, dopamine, histamine, thrombin, kinin, 20 follicle stimulating hormone, opsins, endothelial differentiation gene-1, rhodopsins, odorants, cytomegalovirus, G-proteins themselves, effector proteins such as phospholipase C, adenylyl cyclase, and phosphodiesterase, and actuator proteins such as protein kinase A and protein kinase C.

25

The GPCR protein superfamily now contains over 250 types of paralogues, receptors that represent variants generated by gene duplications (or other processes), as opposed to orthologues, the same receptor from different species. The superfamily can be broken down into five families: Family I, receptors typified by rhodopsin and 30 the β - adrenergic receptor and currently represented by over 200 unique members (reviewed by Dohlman *et al.*, *Ann. Rev. Biochem.* 60, 653-88, 1991, and references

therein); Family II, the recently characterized parathyroid hormone/calcitonin/-
secretin receptor family (Juppner *et al.*, *Science* 254, 1024-26, 1991; Lin *et al.*,
Science 254, 1022-24, 1991); Family III, the metabotropic glutamate receptor family
in mammals (Nakanishi, *Science* 258, 597-603, 1992); Family IV, the cAMP
5 receptor family, important in the chemotaxis and development of *D. discoideum*
(Klein *et al.*, *Science* 241, 1467-72, 1988; and Family V, the fingal mating
pheromone receptors such as STE2 (reviewed by Kurjan, *Ann. Rev. Biochem.* 61,
1097-1129, 1992).

10 GPCRs possess seven conserved membrane-spanning domains connecting at least
eight divergent hydrophilic loops. GPCRs (also known as 7TM receptors) have been
characterized as including these seven conserved hydrophobic stretches of about 20
to 30 amino acids, connecting at least eight divergent hydrophilic loops. Most
GPCRs have single conserved cysteine residues in each of the first two extracellular
15 loops, which form disulfide bonds that are believed to stabilize functional protein
structure. The seven transmembrane regions are designated as TM1, TM2, TM3,
TM4, TM5, TM6, and TM7. TM3 has been implicated in signal transduction.

Phosphorylation and lipidation (palmitoylation or farnesylation) of cysteine residues
20 can influence signal transduction of some GPCRs. Most GPCRs contain potential
phosphorylation sites within the third cytoplasmic loop and/or the carboxy terminus.
For several GPCRs, such as the β -adrenergic receptor, phosphorylation by protein
kinase A and/or specific receptor kinases mediates receptor desensitization.

25 For some receptors, the ligand binding sites of GPCRs are believed to comprise
hydrophilic sockets formed by several GPCR transmembrane domains. The
hydrophilic sockets are surrounded by hydrophobic residues of the GPCRs. The
hydrophilic side of each GPCR transmembrane helix is postulated to face inward and
form a polar ligand binding site. TM3 has been implicated in several GPCRs as
30 having a ligand binding site, such as the TM3 aspartate residue. TM5 serines, a TM6

asparagine, and TM6 or TM7 phenylalanines or tyrosines also are implicated in ligand binding.

GPCRs are coupled inside the cell by heterotrimeric G-proteins to various
5 intracellular enzymes, ion channels, and transporters (*see Johnson et al., Endoc. Rev.*
10, 317-331, 1989). Different G-protein alpha-subunits preferentially stimulate
particular effectors to modulate various biological functions in a cell. Phos-
phorylation of cytoplasmic residues of GPCRs is an important mechanism for the
regulation of some GPCRs. For example, in one form of signal transduction, the
10 effect of hormone binding is the activation inside the cell of the enzyme, adenylate
cyclase. Enzyme activation by hormones is dependent on the presence of the
nucleotide GTP. GTP also influences hormone binding. A G-protein connects the
hormone receptor to adenylate cyclase. G-protein exchanges GTP for bound GDP
when activated by a hormone receptor. The GTP-carrying form then binds to
15 activated adenylate cyclase. Hydrolysis of GTP to GDP, catalyzed by the G-protein
itself, returns the G-protein to its basal, inactive form. Thus, the G-protein serves a
dual role, as an intermediate that relays the signal from receptor to effector, and as a
clock that controls the duration of the signal.

20 Over the past 15 years, nearly 350 therapeutic agents targeting GPCRs receptors have
been successfully introduced onto the market. This indicates that these receptors
have an established, proven history as therapeutic targets. Clearly, there is an on-
going need for identification and characterization of further GPCRs which can play a
role in preventing, ameliorating, or correcting dysfunctions or diseases including, but
25 not limited to, infections such as bacterial, fungal, protozoan, and viral infections,
particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma,
Parkinson's diseases, acute heart failure, hypotension, hypertension, urinary
retention, osteoporosis, angina pectoris, myocardial infarction, ulcers, asthma,
allergies, benign prostatic hypertrophy, and psychotic and neurological disorders,
30 including anxiety, schizophrenia, manic depression, delirium, dementia, several

mental retardation, and dyskinesias, such as Huntington's disease and Tourett's syndrome.

Dopamine and Dopamine Receptors

5

Dopamine is a neurotransmitter that participates in a variety of different functions mediated by the nervous system, including vision, movement, and behavior (see U.S. Patent 5,883,226 and Cooper *et al.*, 1978, *THE BIOCHEMICAL BASIS OF NEUROPHARMACOLOGY*, 3d ed., Oxford University Press, New York, pp, 161-195).

10

The diverse physiological actions of dopamine are in turn mediated by its interaction with two of the basic types of G protein-coupled receptors, D1 and D2, which respectively stimulate and inhibit the enzyme adenylyl cyclase (Kebabian & Calne, 1979, *Nature* 277, 93-96). Alterations in the number or activity of these receptors may be a contributory factor in disease states such as Parkinson's disease (a

15

movement disorder) and schizophrenia (a behavioral disorder).

A great deal of information has accumulated on the biochemistry of the D1 and D2 dopamine receptors, and methods have been developed to solubilize and purify these receptor proteins (see Senogles *et al.*, 1986, *Biochemistry* 25, 749-753; Sengoles *et al.*, 1988, *J. Biol. Chem.* 263, 18996-19002; Gingrich *et al.*, 1988, *Biochemistry* 27, 3907- 3912). The D1 dopamine receptor in several tissues appears to be a glycosylated membrane protein of about 72 kD (Amlaiky *et al.*, 1987, *Mol. Pharmacol.* 31, 129-134; Ninik *et al.*, 1988, *Biochemistry* 27, 7594-7599). The D2 receptor has been suggested to have a higher molecular weight of about 90-150 kD

20

25

(Amlaiky & Caron, 1985, *J. Biol. Chem.* 260, 1983- 1986; Amlaiky & Caron, 1986, *J. Neurochem.* 47, 196-204; Jarvie *et al.*, 1988, *Mol. Pharmacol.* 34, 91-97). Much less is known about a recently discovered additional dopamine receptor, termed D3 (Sokoloff *et al.*, 1990, *Nature* 347, 146-151).

30

Dopamine receptors are primary targets in the clinical treatment of psychomotor disorders such as Parkinson's disease and affective disorders such as schizophrenia

(Seeman *et al.*, 1987, *Neuropsychopharm.* 1, 5-15; Seeman, 1987, *Synapse* 1, 152-333). The three different dopamine receptors (D1, D2, D3) have been cloned as a result of nucleotide sequence homology which exists between these receptor genes (Bunzow *et al.*, 1988, *Nature* 336, 783-787; Grandy *et al.*, 1989, *Proc. Natl. Acad. Sci. USA* 86, 9762-9766; Dal Toso *et al.*, 1989, *EMBO J.* 8, 4025-4034; Zhou *et al.*, 1990, *Nature* 346, 76-80; Sunahara *et al.*, 1990, *Nature* 346, 80-83; Sokoloff *et al.*, 1990, *Nature* 347, 146-151).

The antipsychotic clozapine is useful for socially withdrawn and treatment-resistant schizophrenics (see Kane *et al.*, 1990, *Nature* 347, 146-151), but unlike other antipsychotic drugs, clozapine does not cause tardive dyskinesia (see Casey, 1989, *Psychopharmacology* 99, 547-553). Clozapine, however, has dissociation constants for D2 and D3 which are 3 to 30-fold higher than the therapeutic free concentration of clozapine in plasma water (Ackenheil *et al.*, 1976, *Arzneim-Forsch* 26, 1156-58; Sandoz Canada, Inc., 1990, Clozaril: Summary of preclinical and clinical data). This suggests the existence of dopamine receptors more sensitive to the antipsychotic clozapine than those known in the prior art heretofore.

Because of dopamine's diverse biological effects, there is a need in the art to identify additional members of the dopamine GPCR family whose activity can be regulated to provide therapeutic effects.

SUMMARY OF THE INVENTION

It is an object of the invention to provide reagents and methods of regulating a human dopamine-like G protein-coupled receptor 1 protein. This and other objects of the invention are provided by one or more of the embodiments described below.

One embodiment of the invention is a dopamine-like GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:

amino acid sequences which are at least about 60% identical to the amino acid sequence shown in SEQ ID NO. 2; and

the amino acid sequence shown in SEQ ID NO. 2.

5

Yet another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a dopamine-like GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:

10

amino acid sequences which are at least about 60% identical to the amino acid sequence shown in SEQ ID NO. 2; and

the amino acid sequence shown in SEQ ID NO. 2.

15

Binding between the test compound and the dopamine-like GPCR polypeptide is detected. A test compound which binds to the dopamine-like GPCR polypeptide is thereby identified as a potential agent for decreasing extracellular matrix degradation.

20

Another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a polynucleotide encoding a dopamine-like GPCR polypeptide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:

25

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO. 1; and

the nucleotide sequence shown in SEQ ID NO. 1.

30

Binding of the test compound to the polynucleotide is detected. A test compound which binds to the polynucleotide is identified as a potential agent for decreasing

- 7 -

extracellular matrix degradation. The agent can work by decreasing the amount of the dopamine-like GPCR through interacting with the dopamine-like GPCR mRNA.

5 Another embodiment of the invention is a method of screening for agents which regulate extracellular matrix degradation. A test compound is contacted with a dopamine-like GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:

10 amino acid sequences which are at least about 60% identical to the amino acid sequence shown in SEQ ID NO. 2; and

the amino acid sequence shown in SEQ ID NO. 2.

15 A dopamine-like GPCR activity of the polypeptide is detected. A test compound which increases dopamine-like GPCR activity of the polypeptide relative to dopamine-like GPCR activity in the absence of the test compound is thereby identified as a potential agent for increasing extracellular matrix degradation. A test compound which decreases dopamine-like GPCR activity of the polypeptide relative to dopamine-like GPCR activity in the absence of the test compound is thereby
20 identified as a potential agent for decreasing extracellular matrix degradation.

Even another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a dopamine-like GPCR product of a polynucleotide which comprises a nucleotide
25 sequence selected from the group consisting of:

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO. 1; and

30 the nucleotide sequence shown in SEQ ID NO. 1.

Binding of the test compound to the dopamine-like GPCR product is detected. A test compound which binds to the dopamine-like GPCR product is thereby identified as a potential agent for decreasing extracellular matrix degradation.

5 Still another embodiment of the invention is a method of reducing extracellular matrix degradation. A cell is contacted with a reagent which specifically binds to a polynucleotide encoding a dopamine-like GPCR polypeptide or the product encoded by the polynucleotide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:

10 nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO. 1; and

the nucleotide sequence shown in SEQ ID NO. 1.

15 Dopamine-like GPCR activity in the cell is thereby decreased.

The invention thus provides a human dopamine-like G protein-coupled receptor which can be used to identify test compounds which may act as agonists or
20 antagonists at the receptor site. Human dopamine-like G protein-coupled receptor and fragments thereof also are useful in raising specific antibodies which can block the receptor and effectively prevent ligand binding.

BRIEF DESCRIPTION OF THE DRAWING

25 Fig. 1 shows the DNA-sequence encoding a dopamine-like GPCR polypeptide.

Fig. 2 shows the amino acid sequence deduced from the DNA-sequence of Fig.1.

Fig. 3 shows the amino acid sequence of a protein identified with SwissProt Accession No. P41596.

30 Fig. 4 shows the BLASTX alignment of dopamine-like GPCR polypeptide of Fig.2 with SwissProt Accession No. P41596 of Fig. 3.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to an isolated polynucleotide encoding a dopamine-like GPCR polypeptide and being selected from the group consisting of:

a polynucleotide encoding a dopamine-like GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:

- a) a polynucleotide encoding a galanin receptor-like GPCR polypeptide comprising
an amino acid sequence selected from the group consisting of:
amino acid sequences which are at least about 60% identical to
the amino acid sequence shown in SEQ ID NO. 2; and
the amino acid sequence shown in SEQ ID NO. 2.
- b) a polynucleotide comprising the sequence of SEQ ID NO. 1;
- c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b);
- d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code; and
- e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d)

Furthermore, it has been discovered by the present applicant that a dopamine receptor-like GPCR (DA-like GPCR), particularly a human dopamine receptor-like GPCR, can be used in therapeutic methods to treat disorders such as anxiety,

depression, hypertension, osteoporosis, diabetes, cancer, migraine, compulsive disorders, schizophrenia, autism, neurodegenerative disorders, such as Alzheimer's disease, Parkinsonism, and Huntington's chorea, obesity, and cancer chemotherapy-induced vomiting. Human DA-like GPCR also can be used to screen for human DA-like GPCR agonists and antagonists.

Human DA-like GPCR is 30% identical over 350 amino acids to the *D. melanogaster* protein identified with SwissProt Accession No. P41596 and annotated as a dopamine 1 receptor precursor. Thus, human DA-like GPCR is expected to be useful for the same purposes as previously identified dopamine receptors. For example, human DA-like GPCR made from cloned genes in accordance with the present invention may be used for screening compounds for DA-like GPCR activity or for determining the amount of a dopaminergic drug in a solution (*e.g.*, blood plasma or serum). Host cells transformed with expression vectors comprising human DA-like polynucleotides can be used to screen compounds for DA-like GPCR binding activity. Competitive binding assays in which such procedures may be carried out are well known, as illustrated by the specific examples below. By selection of host cells which do not ordinarily express a dopamine receptor, preparations free of D1A receptors, D2 receptors, and other dopamine receptor subtypes can be obtained. Further, human DA-like GPCR agonists and antagonists can be identified by transforming host cells which express adenylyl cyclase with expression vectors of the present invention. Membranes obtained from such cells can be used in biochemical studies wherein the activity of the adenylyl cyclase is monitored. DA-like GPCR agonists will stimulate the adenylyl cyclase. Such cells must be capable of operatively associating the DA-like GPCR with the adenylyl cyclase, *i.e.*, G protein must also be present in the cell membranes. Procedures for carrying out assays such as these are also described in greater detail in the examples which follow.

Isolated and purified DA-like GPCRs of the present invention also is DA-like GPCR can be purified from cell membranes or lysed cell fractions containing the receptor, as described below, in accordance with known procedures, including column

chromatography (e.g., ion exchange, gel filtration, electrophoresis, affinity chromatography, etc.), optionally followed by crystallization (See generally "Enzyme Purification and Related Techniques," *Methods in Enzymology* 22, 233-577, 1977).

5 Polypeptides

DA-like GPCR polypeptides according to the invention comprise at least 20, 30, 40, 50, 53, 78 100, 125, 150, 175, 200, 250, 300, or 350 contiguous amino acids selected from the amino acid sequence shown in SEQ ID NO.2 or a biologically active variant thereof, as defined below. A DA-like GPCR polypeptide of the invention therefore
10 can be a portion of a DA-like GPCR protein, a full-length DA-like GPCR protein, or a fusion protein comprising all or a portion of a DA-like GPCR protein. A coding sequence for SEQ ID NO. 2 is shown in SEQ ID NO. 1.

15 Biologically Active Variants

DA-like GPCR polypeptide variants which are biologically active, i.e., retain the ability to bind a dopamine or a dopamine-like ligand to produce a biological effect, such as cyclic AMP formation, mobilization of intracellular calcium, or
20 phosphoinositide metabolism, also are DA-like GPCR polypeptides. Preferably, naturally or non-naturally occurring DA-like GPCR polypeptide variants have amino acid sequences which are at least about 60, preferably about 75, 90, 96, or 98% identical to the amino acid sequence shown in SEQ ID NO. 2 or a fragment thereof. Percent identity between a putative DA-like GPCR polypeptide variant and an amino
25 acid sequence of SEQ ID NO. 2 is determined using the Blast2 alignment program (Blosum62, Expect 10, standard genetic codes).

Variations in percent identity can be due, for example, to amino acid substitutions, insertions, or deletions. Amino acid substitutions are defined as one for one amino
30 acid replacements. They are conservative in nature when the substituted amino acid has similar structural and/or chemical properties. Examples of conservative

- 12 -

replacements are substitution of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

Amino acid insertions or deletions are changes to or within an amino acid sequence. They typically fall in the range of about 1 to 5 amino acids. Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological or immunological activity of a DA-like GPCR polypeptide can be found using computer programs well known in the art, such as DNASTAR software. Whether an amino acid change results in a biologically active DA-like GPCR polypeptide can readily be determined by assaying for binding to a ligand or by conducting a functional assay, as described for example, in the specific Examples, below.

Fusion Proteins

Fusion proteins are useful for generating antibodies against DA-like GPCR polypeptide amino acid sequences and for use in various assay systems. For example, fusion proteins can be used to identify proteins which interact with portions of a DA-like GPCR polypeptide. Protein affinity chromatography or library-based assays for protein- protein interactions, such as the yeast two-hybrid or phage display systems, can be used for this purpose. Such methods are well known in the art and also can be used as drug screens.

A DA-like GPCR polypeptide fusion protein comprises two polypeptide segments fused together by means of a peptide bond. The first polypeptide segment comprises at least 20, 30, 40, 50, 53, 78 100, 125, 150, 175, 200, 250, 300, or 350 contiguous amino acids of SEQ ID NO. 2 or of a biologically active variant, such as those described above. The first polypeptide segment also can comprise full-length DA-like GPCR protein.

30

The second polypeptide segment can be a full-length protein or a protein fragment. Proteins commonly used in fusion protein construction include β -galactosidase, β -glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT). Additionally, epitope tags are used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. A fusion protein also can be engineered to contain a cleavage site located between the DA-like GPCR polypeptide-encoding sequence and the heterologous protein sequence, so that the DA-like GPCR polypeptide can be cleaved and purified away from the heterologous moiety.

A fusion protein can be synthesized chemically, as is known in the art. Preferably, a fusion protein is produced by covalently linking two polypeptide segments or by standard procedures in the art of molecular biology. Recombinant DNA methods can be used to prepare fusion proteins, for example, by making a DNA construct which comprises coding sequences selected from SEQ ID NO. 1 in proper reading frame with nucleotides encoding the second polypeptide segment and expressing the DNA construct in a host cell, as is known in the art. Many kits for constructing fusion proteins are available from companies such as Promega Corporation (Madison, WI), Stratagene (La Jolla, CA), CLONTECH (Mountain View, CA), Santa Cruz Biotechnology (Santa Cruz, CA), MBL International Corporation (MIC; Watertown, MA), and Quantum Biotechnologies (Montreal, Canada; 1-888-DNA-KITS).

Identification of Species Homologs

Species homologs of human DA-like GPCR polypeptide can be obtained using DA-like GPCR polypeptide polynucleotides (described below) to make suitable probes or
5 primers for screening cDNA expression libraries from other species, such as mice, monkeys, or yeast, identifying cDNAs which encode homologs of DA-like GPCR polypeptide, and expressing the cDNAs as is known in the art.

Polynucleotides

10

A DA-like GPCR polynucleotide can be single- or double-stranded and comprises a coding sequence or the complement of a coding sequence for a DA-like GPCR polypeptide. A coding sequence for human DA-like GPCR is shown in SEQ ID NO. 1.

15

Degenerate nucleotide sequences encoding human DA-like GPCR polypeptides, as well as homologous nucleotide sequences which are at least about 50, preferably about 75, 90, 96, or 98% identical to the nucleotide sequence shown in SEQ ID NO. 1 also are DA-like GPCR polynucleotides. Percent sequence identity between the
20 sequences of two polynucleotides is determined using computer programs such as ALIGN which employ the FASTA algorithm, using an affine gap search with a gap open penalty of -12 and a gap extension penalty of -2. Complementary DNA (cDNA) molecules, species homologs, and variants of DA-like GPCR polynucleotides which encode biologically active DA-GPCR polypeptides also are DA-like GPCR polynucleotides.
25

Identification of Polynucleotide Variants and Homologs

Variants and homologs of the DA-GPCR polynucleotides described above also are
30 DA-like GPCR polynucleotides. Typically, homologous DA-like GPCR polynucleotide sequences can be identified by hybridization of candidate polynucleotides

- 15 -

to known DA-like GPCR polynucleotides under stringent conditions, as is known in the art. For example, using the following wash conditions--2X SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0), 0.1% SDS, room temperature twice, 30 minutes each; then 2X SSC, 0.1% SDS, 50°C once, 30 minutes; then 2X SSC, room temperature twice, 10 minutes each--homologous sequences can be identified which contain at most about 25-30% basepair mismatches. More preferably, homologous nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches.

Species homologs of the DA-like GPCR polynucleotides disclosed herein also can be identified by making suitable probes or primers and screening cDNA expression libraries from other species, such as mice, monkeys, or yeast. Human variants of DA-like GPCR polynucleotides can be identified, for example, by screening human cDNA expression libraries. It is well known that the T_m of a double-stranded DNA decreases by 1-1.5°C with every 1% decrease in homology (Bonner *et al.*, *J. Mol. Biol.* 81, 123 (1973). Variants of human DA-like GPCR polynucleotides or DA-GPCR polynucleotides of other species can therefore be identified by hybridizing a putative homologous DA-like GPCR polynucleotide with a polynucleotide having a nucleotide sequence of SEQ ID NO. 1 or the complement thereof to form a test hybrid. The melting temperature of the test hybrid is compared with the melting temperature of a hybrid comprising polynucleotides having perfectly complementary nucleotide sequences, and the number or percent of basepair mismatches within the test hybrid is calculated.

Nucleotide sequences which hybridize to DA-like GPCR polynucleotides or their complements following stringent hybridization and/or wash conditions also are DA-like GPCR polynucleotides. Stringent wash conditions are well known and understood in the art and are disclosed, for example, in Sambrook *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL, 2d ed., 1989, at pages 9.50-9.51.

- 16 -

Typically, for stringent hybridization conditions a combination of temperature and salt concentration should be chosen that is approximately 12-20°C below the calculated T_m of the hybrid under study. The T_m of a hybrid between a DA-like GPCR polynucleotide having a nucleotide sequence shown in SEQ ID NO. 1 or the complement thereof and a polynucleotide sequence which is at least about 50, preferably about 75, 90, 96, or 98% identical to one of those nucleotide sequences can be calculated, for example, using the equation of Bolton and McCarthy, *Proc. Natl. Acad. Sci. U.S.A.* 48, 1390 (1962):

$$T_m = 81.5^\circ\text{C} - 16.6(\log_{10}[\text{Na}^+]) + 0.41(\%G + C) - 0.63(\%\text{formamide}) - 600/l,$$

where l = the length of the hybrid in basepairs.

Stringent wash conditions include, for example, 4X SSC at 65°C, or 50% formamide, 4X SSC at 42°C, or 0.5X SSC, 0.1% SDS at 65°C. Highly stringent wash conditions include, for example, 0.2X SSC at 65°C.

Preparation of Polynucleotides

A naturally occurring DA-like GPCR polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids. Polynucleotides can be made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated DA-like GPCR polynucleotides. For example, restriction enzymes and probes can be used to isolate polynucleotide fragments which comprises DA-like GPCR nucleotide sequences. Isolated polynucleotides are in preparations which are free or at least 70, 80, or 90% free of other molecules.

- 17 -

DA-like GPCR cDNA molecules can be made with standard molecular biology techniques, using DA-like GPCR mRNA as a template. DA-like GPCR cDNA molecules can thereafter be replicated using molecular biology techniques known in the art and disclosed in manuals such as Sambrook *et al.* (1989). An amplification technique, such as PCR, can be used to obtain additional copies of polynucleotides of the invention, using either human genomic DNA or cDNA as a template.

Alternatively, synthetic chemistry techniques can be used to synthesize DA-GPCR polynucleotides. The degeneracy of the genetic code allows alternate nucleotide sequences to be synthesized which will encode a DA-like GPCR polypeptide having, for example, an amino acid sequence shown in SEQ ID NO. 2 or a biologically active variant thereof.

Extending Polynucleotides

Various PCR-based methods can be used to extend the nucleic acid sequences disclosed herein to detect upstream sequences such as promoters and regulatory elements. For example, restriction-site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, *PCR Methods Applic.* 2, 318-322, 1993). Genomic DNA is first amplified in the presence of a primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR also can be used to amplify or extend sequences using divergent primers based on a known region (Triglia *et al.*, *Nucleic Acids Res.* 16, 8186, 1988). Primers can be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, Minn.), to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the

target sequence at temperatures about 68-72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

5 Another method which can be used is capture PCR, which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom *et al.*, *PCR Methods Applic. 1*, 111-119, 1991). In this method, multiple restriction enzyme digestions and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment
10 of the DNA molecule before performing PCR.

Another method which can be used to retrieve unknown sequences is that of Parker *et al.*, *Nucleic Acids Res. 19*, 3055-3060, 1991). Additionally, PCR, nested primers, and PROMOTERFINDER libraries (CLONTECH, Palo Alto, Calif.) can be used to
15 walk genomic DNA (CLONTECH, Palo Alto, Calif.). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Randomly-primed libraries are preferable, in
20 that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries can be useful for extension of sequence into 5' non-transcribed regulatory regions.

25 Commercially available capillary electrophoresis systems can be used to analyze the size or confirm the nucleotide sequence of PCR or sequencing products. For example, capillary sequencing can employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device
30 camera. Output/light intensity can be converted to electrical signal using appropriate software (*e.g.* GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and the

entire process from loading of samples to computer analysis and electronic data display can be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

5

Obtaining Polypeptides

DA-like GPCR polypeptides can be obtained, for example, by purification from human cells, by expression of DA-like GPCR polynucleotides, or by direct chemical synthesis.

10

Protein Purification

DA-like GPCR polypeptides can be purified from any human cell which expresses the receptor, including host cells which have been transfected with DA-like GPCR polynucleotides. Melanocytes, fetal heart, and uterus are all particularly useful sources of DA-like GPCR polypeptides. A purified DA-like GPCR polypeptide is separated from other compounds which normally associate with the DA-like GPCR polypeptide in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art. Such methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis.

15

20

DA-like GPCR polypeptide can be conveniently isolated as a complex with its associated G protein, as described in the specific examples, below. A preparation of purified DA-like GPCR polypeptides is at least 80% pure; preferably, the preparations are 90%, 95%, or 99% pure. Purity of the preparations can be assessed by any means known in the art, such as SDS-polyacrylamide gel electrophoresis.

25

Expression of Polynucleotides

To express a DA-like GPCR polynucleotide, the polynucleotide can be inserted into an expression vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art can be used to construct expression vectors containing sequences encoding DA-like GPCR polypeptides and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described, for example, in Sambrook *et al.* (1989) and in Ausubel *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1989.

A variety of expression vector/host systems can be utilized to contain and express sequences encoding a DA-like GPCR polypeptide. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors, insect cell systems infected with virus expression vectors (*e.g.*, baculovirus), plant cell systems transformed with virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmids), or animal cell systems.

The control elements or regulatory sequences are those non-translated regions of the vector -- enhancers, promoters, 5' and 3' untranslated regions -- which interact with host cellular proteins to carry out transcription and translation. Such elements can vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, can be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORT1 plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin promoter can be used in insect cells. Promoters or enhancers derived from the genomes of plant cells

(e.g., heat shock, RUBISCO, and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) can be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding a DA-like GPCR polypeptide, vectors based on SV40 or EBV can be used with an appropriate selectable marker.

Bacterial and Yeast Expression Systems

In bacterial systems, a number of expression vectors can be selected depending upon the use intended for the DA-like GPCR polypeptide. For example, when a large quantity of a DA-like GPCR polypeptide is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene). In a BLUESCRIPT vector, a sequence encoding the DA-like GPCR polypeptide can be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced. pIN vectors (Van Heeke & Schuster, *J. Biol. Chem.* 264, 5503-5509, 1989) or pGEX vectors (Promega, Madison, Wis.) also can be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH can be used. For reviews, see Ausubel *et al.* (1989) and Grant *et al.*, *Methods Enzymol.* 153, 516-544, 1987.

Plant and Insect Expression Systems

If plant expression vectors are used, the expression of sequences encoding DA-like GPCR polypeptides can be driven by any of a number of promoters. For example, 5 viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV (Takamatsu, *EMBO J.* 6, 307-311, 1987). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters can be used (Coruzzi *et al.*, *EMBO J.* 3, 1671-10 1680, 1984; Broglie *et al.*, *Science* 224, 838-843, 1984; Winter *et al.*, *Results Probl. Cell Differ.* 17, 85-105, 1991). These constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (*e.g.*, Hobbs or Murray, in MCGRAW HILL YEARBOOK OF SCIENCE AND TECHNOLOGY, McGraw Hill, New York, 15 N.Y., pp. 191-196, 1992).

An insect system also can be used to express a DA-like GPCR polypeptide. For example, in one such system *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells 20 or in *Trichoplusia* larvae. Sequences encoding DA-like GPCR polypeptides can be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of DA-like GPCR polypeptides will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses can then be used to 25 infect *S. frugiperda* cells or *Trichoplusia* larvae in which DA-like GPCR polypeptides can be expressed (Engelhard *et al.*, *Proc. Nat. Acad. Sci.* 91, 3224-3227, 1994).

Mammalian Expression Systems

A number of viral-based expression systems can be used to express DA-like GPCR polypeptides in mammalian host cells. For example, if an adenovirus is used as an expression vector, sequences encoding DA-like GPCR polypeptides can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome can be used to obtain a viable virus which is capable of expressing a DA-like GPCR polypeptide in infected host cells (Logan & Shenk, *Proc. Natl. Acad. Sci.* 81, 3655-3659, 1984). If desired, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, can be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) also can be used to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6M to 10M are constructed and delivered to cells via conventional delivery methods (e.g., liposomes, polycationic amino polymers, or vesicles).

Specific initiation signals also can be used to achieve more efficient translation of sequences encoding DA-like GPCR polypeptides. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding a DA-like GPCR polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used (see Scharf *et al.*, *Results Probl. Cell Differ.* 20, 125-162, 1994).

Host Cells

5 A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed DA-like GPCR polypeptide in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding and/or function.

10 Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; 10801 University Boulevard, Manassas, VA 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.

15 Stable expression is preferred for long-term, high-yield production of recombinant proteins. For example, cell lines which stably express DA-like GPCR polypeptides can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to a selective medium. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced DA-like GPCR sequences. Resistant clones of stably

20 transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. See, for example, ANIMAL CELL CULTURE, R.I. Freshney, ed., 1986.

Any number of selection systems can be used to recover transformed cell lines.

30 These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler *et al.*, *Cell* 11, 223-32, 1977) and adenine phosphoribosyltransferase (Lowy

5 *et al.*, *Cell* 22, 817-23, 1980) genes which can be employed in *tk⁻* or *aprt⁻* cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate (Wigler *et al.*, *Proc. Natl. Acad. Sci.* 77, 3567-70, 1980), *npt* confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin *et al.*, *J. Mol. Biol.* 150, 1-14, 1981), and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murray, 1992, *supra*). Additional selectable genes have been described. For example, *trpB* allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, *Proc. Natl. Acad. Sci.* 85, 8047-51, 1988). Visible markers such as anthocyanins, β -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes *et al.*, *Methods Mol. Biol.* 55, 121-131, 1995).

15

Detecting Expression

Although the presence of marker gene expression suggests that the DA-like GPCR polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding a DA-like GPCR polypeptide is inserted within a marker gene sequence, transformed cells containing sequences which encode a DA-like GPCR polypeptide can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a DA-like GPCR polypeptide under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the DA-like GPCR polynucleotide.

Alternatively, host cells which contain a DA-like GPCR polynucleotide and which express a DA-like GPCR polypeptide can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay

techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein. For example, the presence of a polynucleotide sequence encoding a DA-like GPCR polypeptide can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding a DA-like GPCR polypeptide. Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding a DA-like GPCR polypeptide to detect transformants which contain a DA-like GPCR polynucleotide.

A variety of protocols for detecting and measuring the expression of a DA-like GPCR polypeptide, using either polyclonal or monoclonal antibodies specific for the polypeptide, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay using monoclonal antibodies reactive to two non-interfering epitopes on a DA-like GPCR polypeptide can be used, or a competitive binding assay can be employed. These and other assays are described in Hampton *et al.*, SEROLOGICAL METHODS: A LABORATORY MANUAL, APS Press, St. Paul, Minn., 1990) and Maddox *et al.*, *J. Exp. Med.* 158, 1211-1216, 1983).

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding DA-like GPCR polypeptides include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, sequences encoding a DA-like GPCR polypeptide can be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and can be used to synthesize RNA probes *in vitro* by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical).

Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

5 Expression and Purification of Polypeptides

Host cells transformed with nucleotide sequences encoding a DA-like GPCR polypeptide can be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The polypeptide produced by a transformed cell can
10 be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode DA-like GPCR polypeptides can be designed to contain signal sequences which direct secretion of soluble DA-like GPCR polypeptides through a prokaryotic or eukaryotic cell membrane or which direct the
15 membrane insertion of membrane-bound DA-like GPCR polypeptide.

As discussed above, other constructions can be used to join a sequence encoding a DA-like GPCR polypeptide to a nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating
20 domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). Inclusion of cleavable linker sequences such as those specific for
25 Factor Xa or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the DA-like GPCR polypeptide also can be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a DA-like GPCR polypeptide and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC
30 (immobilized metal ion affinity chromatography, as described in Porath *et al.*, *Prot. Exp. Purif.* 3, 263-281, 1992), while the enterokinase cleavage site provides a means

for purifying the DA-like GPCR polypeptide from the fusion protein. Vectors which contain fusion proteins are disclosed in Kroll *et al.*, *DNA Cell Biol.* 12, 441-453, 1993.

5 Chemical Synthesis

Sequences encoding a DA-like GPCR polypeptide can be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers *et al.*, *Nucl. Acids Res. Symp. Ser.* 215-223, 1980; Horn *et al.* *Nucl. Acids Res. Symp. Ser.* 225-232, 10 1980). Alternatively, a DA-like GPCR polypeptide itself can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques (Merrifield, *J. Am. Chem. Soc.* 85, 2149-2154, 1963; Roberge *et al.*, *Science* 269, 202-204, 1995). Protein synthesis can be performed using manual techniques or by automation. Automated synthesis can be 15 achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Optionally, fragments of DA-like GPCR polypeptides can be separately synthesized and combined using chemical methods to produce a full-length molecule.

20 The newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography (*e.g.*, Creighton, *PROTEINS: STRUCTURES AND MOLECULAR PRINCIPLES*, WH Freeman and Co., New York, N.Y., 1983). The composition of a synthetic DA-like GPCR polypeptide can be confirmed by amino acid analysis or sequencing (*e.g.*, the Edman degradation procedure; *see* Creighton, 25 *supra*). Additionally, any portion of the amino acid sequence of the DA-like GPCR polypeptide can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.

Production of Altered Polypeptides

As will be understood by those of skill in the art, it may be advantageous to produce DA-like GPCR polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences disclosed herein can be engineered using methods generally known in the art to alter DA-like GPCR polypeptide-encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or mRNA product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides can be used to engineer the nucleotide sequences. For example, site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

Antibodies

Any type of antibody known in the art can be generated to bind specifically to an epitope of a DA-like GPCR polypeptide. "Antibody" as used herein includes intact immunoglobulin molecules, as well as fragments thereof, such as Fab, F(ab')₂, and Fv, which are capable of binding an epitope of a DA-like GPCR polypeptide. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. However, epitopes which involve non-contiguous amino acids may require more, e.g., at least 15, 25, or 50 amino acids.

An antibody which specifically binds to an epitope of a DA-like GPCR polypeptide can be used therapeutically, as well as in immunochemical assays, such as Western

blots, ELISAs, radioimmunoassays, immunohistochemical assays, immuno-precipitations, or other immunochemical assays known in the art. Various immunoassays can be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays are well known in the art. Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody which specifically binds to the immunogen.

Typically, an antibody which specifically binds to a DA-like GPCR polypeptide provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an immunochemical assay. Preferably, antibodies which specifically bind to DA-like GPCR polypeptides do not detect other proteins in immunochemical assays and can immunoprecipitate a DA-like GPCR polypeptide from solution.

DA-like GPCR polypeptides can be used to immunize a mammal, such as a mouse, rat, rabbit, guinea pig, monkey, or human, to produce polyclonal antibodies. If desired, a DA-like GPCR polypeptide can be conjugated to a carrier protein, such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin. Depending on the host species, various adjuvants can be used to increase the immunological response. Such adjuvants include, but are not limited to, Freund's adjuvant, mineral gels (e.g., aluminum hydroxide), and surface active substances (e.g. lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol). Among adjuvants used in humans, BCG (*bacilli Calmette-Guerin*) and *Corynebacterium parvum* are especially useful.

Monoclonal antibodies which specifically bind to a DA-like GPCR polypeptide can be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These techniques include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler *et al.*, *Nature* 256, 495-497, 1985; Kozbor *et al.*,

J. Immunol. Methods 81, 31-42, 1985; Cote *et al.*, *Proc. Natl. Acad. Sci.* 80, 2026-2030, 1983; Cole *et al.*, *Mol. Cell Biol.* 62, 109-120, 1984).

5 In addition, techniques developed for the production of "chimeric antibodies," the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used (Morrison *et al.*, *Proc. Natl. Acad. Sci.* 81, 6851-6855, 1984; Neuberger *et al.*, *Nature* 312, 604-608, 1984; Takeda *et al.*, *Nature* 314, 452-454, 1985). Monoclonal and other antibodies also can be "humanized" to prevent a patient from mounting an immune response
10 against the antibody when it is used therapeutically. Such antibodies may be sufficiently similar in sequence to human antibodies to be used directly in therapy or may require alteration of a few key residues. Sequence differences between rodent antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual
15 residues or by grating of entire complementarity determining regions. Alternatively, humanized antibodies can be produced using recombinant methods, as described in GB2188638B. Antibodies which specifically bind to a DA-like GPCR polypeptide can contain antigen binding sites which are either partially or fully humanized, as disclosed in U.S. 5,565,332.

20 Alternatively, techniques described for the production of single chain antibodies can be adapted using methods known in the art to produce single chain antibodies which specifically bind to DA-like GPCR polypeptides. Antibodies with related specificity, but of distinct idiotypic composition, can be generated by chain shuffling from
25 random combinatorial immunoglobulin libraries (Burton, *Proc. Natl. Acad. Sci.* 88, 11120-23, 1991).

Single-chain antibodies also can be constructed using a DNA amplification method, such as PCR, using hybridoma cDNA as a template (Thirion *et al.*, 1996, *Eur. J. Cancer Prev.* 5, 507-11).
30 Single-chain antibodies can be mono- or bispecific, and can be bivalent or tetravalent. Construction of tetravalent, bispecific single-chain

antibodies is taught, for example, in Coloma & Morrison, 1997, *Nat. Biotechnol.* 15, 159-63. Construction of bivalent, bispecific single-chain antibodies is taught in Mallender & Voss, 1994, *J. Biol. Chem.* 269, 199-206.

5 A nucleotide sequence encoding a single-chain antibody can be constructed using manual or automated nucleotide synthesis, cloned into an expression construct using standard recombinant DNA methods, and introduced into a cell to express the coding sequence, as described below. Alternatively, single-chain antibodies can be produced directly using, for example, filamentous phage technology (Verhaar *et al.*,
10 1995, *Int. J. Cancer* 61, 497-501; Nicholls *et al.*, 1993, *J. Immunol. Meth.* 165, 81-91).

Antibodies which specifically bind to DA-like GPCR polypeptides also can be produced by inducing *in vivo* production in the lymphocyte population or by
15 screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi *et al.*, *Proc. Natl. Acad. Sci.* 86, 3833-3837, 1989; Winter *et al.*, *Nature* 349, 293-299, 1991).

Other types of antibodies can be constructed and used therapeutically in methods of
20 the invention. For example, chimeric antibodies can be constructed as disclosed in WO 93/03151. Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the "diabodies" described in WO 94/13804, also can be prepared.

25 Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which a DA-like GPCR polypeptide is bound. The bound antibodies can then be eluted from the column using a buffer with a high salt concentration.

Antisense Oligonucleotides

Antisense oligonucleotides are nucleotide sequences which are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation. Preferably, an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used. Antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a cell as described above to decrease the level of DA-like GPCR gene products in the cell.

Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such as alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters. See Brown, *Meth. Mol. Biol.* 20, 1-8, 1994; Sonveaux, *Meth. Mol. Biol.* 26, 1-72, 1994; Uhlmann *et al.*, *Chem. Rev.* 90, 543-583, 1990.

Modifications of DA-like GPCR gene expression can be obtained by designing antisense oligonucleotides which will form duplexes to the control, 5', or regulatory regions of the DA-like GPCR gene. Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons. Therapeutic advances using triplex DNA have been described in the literature (e.g., Gee *et al.*, in Huber & Carr, MOLECULAR AND IMMUNOLOGIC

- 34 -

APPROACHES, Futura Publishing Co., Mt. Kisco, N.Y., 1994). An antisense oligonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

5 Precise complementarity is not required for successful complex formation between an antisense oligonucleotide and the complementary sequence of a DA-like GPCR polynucleotide. Antisense oligonucleotides which comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to a DA-like GPCR polynucleotide, each separated by a stretch of contiguous
10 nucleotides which are not complementary to adjacent DA-like GPCR nucleotides, can provide sufficient targeting specificity for DA-like GPCR mRNA. Preferably, each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length. Non-complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in length. One skilled in the art can easily use the
15 calculated melting point of an antisense-sense pair to determine the degree of mismatching which will be tolerated between a particular antisense oligonucleotide and a particular DA-like GPCR polynucleotide sequence.

Antisense oligonucleotides can be modified without affecting their ability to
20 hybridize to a DA-like GPCR polynucleotide. These modifications can be internal or at one or both ends of the antisense molecule. For example, internucleoside phosphate linkages can be modified by adding cholesteryl or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose. Modified bases and/or sugars, such as arabinose instead of ribose, or a 3', 5'-
25 substituted oligonucleotide in which the 3' hydroxyl group or the 5' phosphate group are substituted, also can be employed in a modified antisense oligonucleotide. These modified oligonucleotides can be prepared by methods well known in the art. See, e.g., Agrawal *et al.*, *Trends Biotechnol.* 10, 152-158, 1992; Uhlmann *et al.*, *Chem. Rev.* 90, 543-584, 1990; Uhlmann *et al.*, *Tetrahedron. Lett.* 215, 3539-3542, 1987.

30

Ribozymes

Ribozymes are RNA molecules with catalytic activity. *See, e.g., Cech, Science 236, 1532-1539; 1987; Cech, Ann. Rev. Biochem. 59, 543-568; 1990, Cech, Curr. Opin. Struct. Biol. 2, 605-609; 1992, Couture & Stinchcomb, Trends Genet. 12, 510-515, 1996.* Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art (*e.g., Haseloff et al., U.S. Patent 5,641,673*). The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide sequences.

The coding sequence of a DA-like GPCR polynucleotide, such as the nucleotide sequence shown in SEQ ID NO. 1, can be used to generate ribozymes which will specifically bind to mRNA transcribed from the DA-like GPCR polynucleotide. Methods of designing and constructing ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art (*see Haseloff et al. Nature 334, 585-591, 1988*). For example, the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme. The hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target (*see, for example, Gerlach et al., EP 321,201*).

Specific ribozyme cleavage sites within a DA-like GPCR RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of candidate DA-like GPCR RNA targets also can be evaluated by testing accessibility to hybridization

with complementary oligonucleotides using ribonuclease protection assays. The nucleotide sequence shown in SEQ ID NO. 1 and its complement provide a source of suitable hybridization region sequences. Longer complementary sequences can be used to increase the affinity of the hybridization sequence for the target. The hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.

Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct into cells in which it is desired to decrease DA-like GPCR expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art. A ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells.

As taught in Haseloff *et al.*, U.S. Patent 5,641,673, ribozymes can be engineered so that ribozyme expression will occur in response to factors which induce expression of a target gene. Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.

Screening Methods

The invention provides assays for screening test compounds which bind to or modulate the activity of a DA-like GPCR polypeptide or a DA-like GPCR polynucleotide. A test compound preferably binds to a DA-like GPCR polypeptide or polynucleotide. More preferably, a test compound decreases or increases the

effect of dopamine or a dopamine analog as mediated via human DA-like GPCR by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the test compound.

5 Test Compounds

Test compounds can be pharmacologic agents already known in the art or can be compounds previously unknown to have any pharmacological activity. The compounds can be naturally occurring or designed in the laboratory. They can be
10 isolated from microorganisms, animals, or plants, and can be produced re-combinantly, or synthesized by chemical methods known in the art. If desired, test compounds can be obtained using any of the numerous combinatorial library methods known in the art, including but not limited to, biological libraries, spatially addressable parallel solid phase or solution phase libraries, synthetic library methods
15 requiring deconvolution, the "one-bead one-compound" library method, and synthetic library methods using affinity chromatography selection. The biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide oligomer, or small molecule libraries of compounds. See Lam, *Anticancer Drug Des.* 12, 145, 1997.

20 Methods for the synthesis of molecular libraries are well known in the art (see, for example, DeWitt *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 90, 6909, 1993; Erb *et al.* *Proc. Natl. Acad. Sci. U.S.A.* 91, 11422, 1994; Zuckermann *et al.*, *J. Med. Chem.* 37, 2678, 1994; Cho *et al.*, *Science* 261, 1303, 1993; Carell *et al.*, *Angew. Chem. Int. Ed. Engl.* 33, 2059, 1994; Carell *et al.*, *Angew. Chem. Int. Ed. Engl.* 33, 2061; Gallop *et al.*, *J. Med. Chem.* 37, 1233, 1994). Libraries of compounds can be presented in solution
25 (see, e.g., Houghten, *BioTechniques* 13, 412-421, 1992), or on beads (Lam, *Nature* 354, 82-84, 1991), chips (Fodor, *Nature* 364, 555-556, 1993), bacteria or spores (Ladner, U.S. Patent 5,223,409), plasmids (Cull *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 89, 1865-1869, 1992), or phage (Scott & Smith, *Science* 249, 386-390, 1990; Devlin,
30

Science 249, 404-406, 1990); Cwirla *et al.*, *Proc. Natl. Acad. Sci.* 97, 6378-6382, 1990; Felici, *J. Mol. Biol.* 222, 301-310, 1991; and Ladner, U.S. Patent 5,223,409).

High Throughput Screening

5

Test compounds can be screened for the ability to bind to DA-like GPCR polypeptides or polynucleotides or to affect DA-like GPCR activity or DA-like GPCR gene expression using high throughput screening. Using high throughput screening, many discrete compounds can be tested in parallel so that large numbers of test compounds can be quickly screened. The most widely established techniques utilize 96-well microtiter plates. The wells of the microtiter plates typically require assay volumes that range from 50 to 500 μ l. In addition to the plates, many instruments, materials, pipettors, robotics, plate washers, and plate readers are commercially available to fit the 96-well format.

15

Alternatively, "free format assays," or assays that have no physical barrier between samples, can be used. For example, an assay using pigment cells (melanocytes) in a simple homogeneous assay for combinatorial peptide libraries is described by Jayawickreme *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 19, 1614-18 (1994). The cells are placed under agarose in petri dishes, then beads that carry combinatorial compounds are placed on the surface of the agarose. The combinatorial compounds are partially released the compounds from the beads. Active compounds can be visualized as dark pigment areas because, as the compounds diffuse locally into the gel matrix, the active compounds cause the cells to change colors.

25

Another example of a free format assay is described by Chelsky, "Strategies for Screening Combinatorial Libraries: Novel and Traditional Approaches," reported at the First Annual Conference of The Society for Biomolecular Screening in Philadelphia, Pa. (Nov. 7-10, 1995). Chelsky placed a simple homogenous enzyme assay for carbonic anhydrase inside an agarose gel such that the enzyme in the gel would cause a color change throughout the gel. Thereafter, beads carrying

30

- 39 -

combinatorial compounds via a photolinker were placed inside the gel and the compounds were partially released by UV-light. Compounds that inhibited the enzyme were observed as local zones of inhibition having less color change.

5 Yet another example is described by Salmon *et al.*, *Molecular Diversity* 2, 57-63 (1996). In this example, combinatorial libraries were screened for compounds that had cytotoxic effects on cancer cells growing in agar.

10 Another high throughput screening method is described in Beutel *et al.*, U.S. Patent 5,976,813. In this method, test samples are placed in a porous matrix. One or more assay components are then placed within, on top of, or at the bottom of a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support. When samples are introduced to the porous matrix they diffuse sufficiently slowly, such that the assays can be performed without the test samples running together.

15

Binding Assays

For binding assays, the test compound is preferably a small molecule which binds to and occupies the active site of the DA-like GPCR polypeptide, thereby making the
20 ligand binding site inaccessible to substrate such that normal biological activity is prevented. Examples of such small molecules include, but are not limited to, small peptides or peptide-like molecules. Potential ligands which bind to a polypeptide of the invention include, but are not limited to, the natural ligands of known DA-like GPCRs and analogues or derivatives thereof.

25

In binding assays, either the test compound or the DA-like GPCR polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase. Detection of a test compound which is bound to the DA-like GPCR
30 polypeptide can then be accomplished, for example, by direct counting of

radioemmission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product.

Alternatively, binding of a test compound to a DA-like GPCR polypeptide can be
5 determined without labeling either of the interactants. For example, a micro-
physiometer can be used to detect binding of a test compound with a DA-like GPCR
polypeptide. A microphysiometer (*e.g.*, Cytosensor™) is an analytical instrument
that measures the rate at which a cell acidifies its environment using a light-
addressable potentiometric sensor (LAPS). Changes in this acidification rate can be
10 used as an indicator of the interaction between a test compound and a DA-like GPCR
polypeptide (McConnell *et al.*, *Science* 257, 1906-1912, 1992).

Determining the ability of a test compound to bind to a DA-like GPCR polypeptide
also can be accomplished using a technology such as real-time Bimolecular
15 Interaction Analysis (BIA) (Sjolander & Urbaniczky, *Anal. Chem.* 63, 2338-2345,
1991, and Szabo *et al.*, *Curr. Opin. Struct. Biol.* 5, 699-705, 1995). BIA is a
technology for studying biospecific interactions in real time, without labeling any of
the interactants (*e.g.*, BIAcore™). Changes in the optical phenomenon surface
plasmon resonance (SPR) can be used as an indication of real-time reactions between
20 biological molecules.

In yet another aspect of the invention, a DA-like GPCR polypeptide can be used as a
"bait protein" in a two-hybrid assay or three-hybrid assay (see, *e.g.*, U.S. Patent
5,283,317; Zervos *et al.*, *Cell* 72, 223-232, 1993; Madura *et al.*, *J. Biol. Chem.* 268,
25 12046-12054, 1993; Bartel *et al.*, *BioTechniques* 14, 920-924, 1993; Iwabuchi *et al.*,
Oncogene 8, 1693-1696, 1993; and Brent W094/10300), to identify other proteins
which bind to or interact with the DA-GPCR polypeptide and modulate its activity.

The two-hybrid system is based on the modular nature of most transcription factors,
30 which consist of separable DNA-binding and activation domains. Briefly, the assay
utilizes two different DNA constructs. For example, in one construct, polynucleotide

encoding a DA-like GPCR polypeptide can be fused to a polynucleotide encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct a DNA sequence that encodes an unidentified protein ("prey" or "sample") can be fused to a polynucleotide that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact *in vivo* to form an protein-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ), which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the DNA sequence encoding the protein which interacts with the DA-like GPCR polypeptide.

It may be desirable to immobilize either the DA-like GPCR polypeptide (or polynucleotide) or the test compound to facilitate separation of bound from unbound forms of one or both of the interactants, as well as to accommodate automation of the assay. Thus, either the DA-like GPCR polypeptide (or polynucleotide) or the test compound can be bound to a solid support. Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads). Any method known in the art can be used to attach the DA-like GPCR polypeptide (or polynucleotide) or test compound to a solid support, including use of covalent and non-covalent linkages, passive absorption, or pairs of binding moieties attached respectively to the polypeptide (or polynucleotide) or test compound and the solid support. Test compounds are preferably bound to the solid support in an array, so that the location of individual test compounds can be tracked. Binding of a test compound to a DA-like GPCR polypeptide (or polynucleotide) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.

In one embodiment, the DA-like GPCR polypeptide is a fusion protein comprising a domain that allows the DA-like GPCR polypeptide to be bound to a solid support. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and the non-adsorbed DA-like GPCR polypeptide; the mixture is then incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components. Binding of the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can be dissociated from the solid support before binding is determined.

Other techniques for immobilizing proteins or polynucleotides on a solid support also can be used in the screening assays of the invention. For example, either a DA-like GPCR polypeptide (or polynucleotide) or a test compound can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated DA-like GPCR polypeptides (or polynucleotides) or test compounds can be prepared from biotin-NHS(N-hydroxysuccinimide) using techniques well known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.) and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies which specifically bind to a DA-like GPCR polypeptide, polynucleotide, or a test compound, but which do not interfere with a desired binding site, such as the active site of the DA-like GPCR polypeptide, can be derivatized to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation.

Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies which specifically bind to the DA-like GPCR polypeptide or test compound, enzyme-linked assays which rely on detecting an activity of the DA-like GPCR polypeptide, and SDS gel electrophoresis under non-reducing conditions.

Screening for test compounds which bind to a DA-like GPCR polypeptide or polynucleotide also can be carried out in an intact cell. Any cell which comprises a DA-like GPCR polypeptide or polynucleotide can be used in a cell-based assay system. A DA-like GPCR polynucleotide can be naturally occurring in the cell or
5 can be introduced using techniques such as those described above. Binding of the test compound to a DA-like GPCR polypeptide or polynucleotide is determined as described above.

Functional Assays

10

Test compounds can be tested for the ability to increase or decrease a biological effect of a DA-like GPCR polypeptide. Such biological effects can be determined using the functional assays described in the specific examples, below. Functional assays can be carried out after contacting either a purified DA-like GPCR
15 polypeptide, a cell membrane preparation, or an intact cell with a test compound. A test compound which decreases a functional activity of a DA-like GPCR by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential agent for decreasing DA-like GPCR activity. A test compound which increases DA-like GPCR activity by at least about 10, preferably about 50, more
20 preferably about 75, 90, or 100% is identified as a potential agent for increasing DA-GPCR activity.

One such screening procedure involves the use of melanophores which are transfected to express a DA-GPCR polypeptide. Such a screening technique is
25 described in WO 92/01810 published Feb. 6, 1992. Thus, for example, such an assay may be employed for screening for a compound which inhibits activation of the receptor polypeptide by contacting the melanophore cells which comprise the receptor with both the receptor ligand (e.g., dopamine or a dopamine analog) and a test compound to be screened. Inhibition of the signal generated by the ligand
30 indicates that a test compound is a potential antagonist for the receptor, *i.e.*, inhibits activation of the receptor. The screen may be employed for identifying a test

compound which activates the receptor by contacting such cells with compounds to be screened and determining whether each test compound generates a signal, *i.e.*, activates the receptor.

- 5 Other screening techniques include the use of cells which express a human DA-like GPCR polypeptide (for example, transfected CHO cells) in a system which measures extracellular pH changes caused by receptor activation (*see, e.g., Science* 246, 181-296, 1989). For example, test compounds may be contacted with a cell which expresses a human DA-like GPCR polypeptide and a second messenger response,
10 *e.g.*, signal transduction or pH changes, can be measured to determine whether the test compound activates or inhibits the receptor.

- Another such screening technique involves introducing RNA encoding a human DA-like GPCR polypeptide into *Xenopus* oocytes to transiently express the receptor. The
15 transfected oocytes can then be contacted with the receptor ligand and a test compound to be screened, followed by detection of inhibition or activation of a calcium signal in the case of screening for test compounds which are thought to inhibit activation of the receptor.

- 20 Another screening technique involves expressing a human DA-like GPCR polypeptide in cells in which the receptor is linked to a phospholipase C or D. Such cells include endothelial cells, smooth muscle cells, embryonic kidney cells, etc. The screening may be accomplished as described above by quantifying the degree of activation of the receptor from changes in the phospholipase activity.

- 25 Details of functional assays such as those described above are provided in the specific examples, below.

Gene Expression

In another embodiment, test compounds which increase or decrease DA-like GPCR gene expression are identified. A DA-like GPCR polynucleotide is contacted with a test compound, and the expression of an RNA or polypeptide product of the DA-like GPCR polynucleotide is determined. The level of expression of appropriate mRNA or polypeptide in the presence of the test compound is compared to the level of expression of mRNA or polypeptide in the absence of the test compound. The test compound can then be identified as a modulator of expression based on this comparison. For example, when expression of mRNA or polypeptide is greater in the presence of the test compound than in its absence, the test compound is identified as a stimulator or enhancer of the mRNA or polypeptide expression. Alternatively, when expression of the mRNA or polypeptide is less in the presence of the test compound than in its absence, the test compound is identified as an inhibitor of the mRNA or polypeptide expression.

The level of DA-like GPCR mRNA or polypeptide expression in the cells can be determined by methods well known in the art for detecting mRNA or polypeptide. Either qualitative or quantitative methods can be used. The presence of polypeptide products of a DA-like GPCR polynucleotide can be determined, for example, using a variety of techniques known in the art, including immunochemical methods such as radioimmunoassay, Western blotting, and immunohistochemistry. Alternatively, polypeptide synthesis can be determined *in vivo*, in a cell culture, or in an *in vitro* translation system by detecting incorporation of labeled amino acids into a DA-like GPCR polypeptide.

Such screening can be carried out either in a cell-free assay system or in an intact cell. Any cell which expresses a DA-like GPCR polynucleotide can be used in a cell-based assay system. The DA-like GPCR polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described

above. Either a primary culture or an established cell line, such as CHO or human embryonic kidney 293 cells, can be used.

Pharmaceutical Compositions

5

The invention also provides pharmaceutical compositions which can be administered to a patient to achieve a therapeutic effect. Pharmaceutical compositions of the invention can comprise, for example, a DA-like GPCR polypeptide, DA-like GPCR polynucleotide, antibodies which specifically bind to a DA-like GPCR polypeptide, 10 or mimetics, agonists, antagonists, or inhibitors of a DA-like GPCR polypeptide activity. The compositions can be administered alone or in combination with at least one other agent, such as stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions can be administered to a 15 patient alone, or in combination with other agents, drugs or hormones.

In addition to the active ingredients, these pharmaceutical compositions can contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be 20 used pharmaceutically. Pharmaceutical compositions of the invention can be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means. Pharmaceutical compositions for oral administration can be formulated using 25 pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

30 Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and

processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which also can contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame

oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino polymers also can be used for delivery. Optionally, the suspension also can contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention can be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. The pharmaceutical composition can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation can be a lyophilized powder which can contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

Further details on techniques for formulation and administration can be found in the latest edition of REMINGTON'S PHARMACEUTICAL SCIENCES (Maack Publishing Co., Easton, Pa.). After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration.

Therapeutic Indications and Methods

GPCRs are ubiquitous in the mammalian host and are responsible for many biological functions, including many pathologies. Accordingly, it is desirable to find compounds and drugs which stimulate a GPCR on the one hand and which can

inhibit the function of a GPCR on the other hand. For example, compounds which activate a GPCR may be employed for therapeutic purposes, such as the treatment of asthma, Parkinson's disease, acute heart failure, urinary retention, and osteoporosis. In particular, compounds which activate GPCRs are useful in treating various cardiovascular ailments such as caused by the lack of pulmonary blood flow or hypertension. In addition these compounds may also be used in treating various physiological disorders relating to abnormal control of fluid and electrolyte homeostasis and in diseases associated with abnormal angiotensin-induced aldosterone secretion.

In general, compounds which inhibit activation of a GPCR can be used for a variety of therapeutic purposes, for example, for the treatment of hypotension and/or hypertension, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders including schizophrenia, manic excitement, depression, delirium, dementia or severe mental retardation, dyskinesias, such as Huntington's disease or Tourett's syndrome, among others. Compounds which inhibit GPCRs also are useful in reversing endogenous anorexia, in the control of bulimia, and in treating various cardiovascular ailments such as caused by excessive pulmonary blood flow or hypotension. In particular, regulation of DA-like GPCR can be used to treat anxiety, depression, hypertension, migraine, compulsive disorders, schizophrenia, autism, neurodegenerative disorders, such as Alzheimer's disease, Parkinsonism, and Huntington's chorea, and cancer chemotherapy-induced vomiting, as well as sleep and eating disorders, pain control, disorders involving regulation of body temperature and blood pressure.

This gene, translated proteins and agents which modulate this gene or portions of the gene or its products are useful for treating obesity, overweight, anorexia, cachexia, wasting disorders, appetite suppression, appetite enhancement, increases or decreases in satiety, modulation of body weight, and/or other eating disorders such as bulimia. Obesity and overweight are defined as an excess of body fat relative to lean body mass. An increase in caloric intake or a decrease in energy expenditure or both can

bring about this imbalance leading to surplus energy being stored as fat. Obesity is associated with important medical morbidities and an increase in mortality. The causes of obesity are poorly understood and may be due to genetic factors, environmental factors or a combination of the two to cause a positive energy balance.

5 In contrast, anorexia and cachexia are characterized by an imbalance in energy intake versus energy expenditure leading to a negative energy balance and weight loss. Agents that either increase energy expenditure and/or decrease energy intake, absorption or storage would be useful for treating obesity, overweight, and associated comorbidities. Agents that either increase energy intake and/or decrease energy

10 expenditure or increase the amount of lean tissue would be useful for treating cachexia, anorexia and wasting disorders.

This gene, translated proteins and agents which modulate this gene or portions of the gene or its products also are useful for treating obesity/overweight-associated

15 comorbidities including hypertension, type 2 diabetes, coronary artery disease, hyperlipidemia, stroke, gallbladder disease, gout, osteoarthritis, sleep apnea and respiratory problems, some types of cancer including endometrial, breast, prostate and colon cancer, thrombotic disease, polycystic ovarian syndrome; reduced fertility, complications of pregnancy, menstrual irregularities, hirsutism, stress incontinence,

20 and depression.

Human DA-like GPCRs provide a potential target for treating cancer. Cancer is a disease fundamentally caused by oncogenic cellular transformation. There are several hallmarks of transformed cells that distinguish them from their normal

25 counterparts and underlie the pathophysiology of cancer. These include uncontrolled cellular proliferation, unresponsiveness to normal death-inducing signals (immortalization), increased cellular motility and invasiveness, increased ability to recruit blood supply through induction of new blood vessel formation (angiogenesis), genetic instability, and dysregulated gene expression. Various combinations of these

30 aberrant physiologies, along with the acquisition of drug-resistance frequently lead to an intractable disease state in which organ failure and patient death ultimately ensue.

Most standard cancer therapies target cellular proliferation and rely on the differential proliferative capacities between transformed and normal cells for their efficacy. This approach is hindered by the facts that several important normal cell types are also highly proliferative and that cancer cells frequently become resistant to these agents. Thus, the therapeutic indices for traditional anti-cancer therapies rarely exceed 2.0.

The advent of genomics-driven molecular target identification has opened up the possibility of identifying new cancer-specific targets for therapeutic intervention that will provide safer, more effective treatments for cancer patients. Thus, newly discovered tumor-associated genes and their products can be tested for their role(s) in disease and used as tools to discover and develop innovative therapies. Genes playing important roles in any of the physiological processes outlined above can be characterized as cancer targets.

Genes or gene fragments identified through genomics can readily be expressed in one or more heterologous expression systems to produce functional recombinant proteins. These proteins are characterized *in vitro* for their biochemical properties and then used as tools in high-throughput molecular screening programs to identify chemical modulators of their biochemical activities. Agonists and/or antagonists of target protein activity can be identified in this manner and subsequently tested in cellular and *in vivo* disease models for anti-cancer activity. Optimization of lead compounds with iterative testing in biological models and detailed pharmacokinetic and toxicological analyses form the basis for drug development and subsequent testing in humans.

Diabetes also can be potentially treated by regulating the activity of human DA-like GPCR. Diabetes mellitus is a common metabolic disorder characterized by an abnormal elevation in blood glucose, alterations in lipids and abnormalities (complications) in the cardiovascular system, eye, kidney and nervous system.

Diabetes is divided into two separate diseases: type 1 diabetes (juvenile onset) that results from a loss of cells which make and secrete insulin, and type 2 diabetes (adult onset) which is caused by a defect in insulin secretion and a defect in insulin action.

5 Type 1 diabetes is initiated by an autoimmune reaction that attacks the insulin secreting cells (beta cells) in the pancreatic islets. Agents that prevent this reaction from occurring or that stop the reaction before destruction of the beta cells has been accomplished are potential therapies for this disease. Other agents that induce beta cell proliferation and regeneration are also potential therapies.

10

 Type II diabetes is the most common of the two diabetic conditions (6% of the population). The defect in insulin secretion is an important cause of the diabetic condition and results from an inability of the beta cell to properly detect and respond to rises in blood glucose levels with insulin release. Therapies that increase the response by the beta cell to glucose would offer an important new treatment for this disease.

15

 The defect in insulin action in Type II diabetic subjects is another target for therapeutic intervention. Agents that increase the activity of the insulin receptor in muscle, liver and fat will cause a decrease in blood glucose and a normalization of plasma lipids. The receptor activity can be increased by agents that directly stimulate the receptor or that increase the intracellular signals from the receptor. Other therapies can directly activate the cellular end process, *i.e.* glucose transport or various enzyme systems, to generate an insulin-like effect and therefore a produce beneficial outcome. Because overweight subjects have a greater susceptibility to Type II diabetes, any agent that reduces body weight is a possible therapy.

20

25

 Both Type I and Type diabetes can be treated with agents that mimic insulin action or that treat diabetic complications by reducing blood glucose levels. Likewise agents that reduces new blood vessel growth can be used to treat the eye complications that develop in both diseases.

30

Osteoporosis, too, can potentially be treated by regulating human DA-like GPCR. Osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk. It is the most common human metabolic bone disorder. Established osteoporosis includes the presence of fractures.

Bone turnover occurs by the action of two major effector cell types within bone: the osteoclast, which is responsible for bone resorption, and the osteoblast, which synthesizes and mineralizes bone matrix. The actions of osteoclasts and osteoblasts are highly coordinated. Osteoclast precursors are recruited to the site of turnover; they differentiate and fuse to form mature osteoclasts which then resorb bone. Attached to the bone surface, osteoclasts produce an acidic microenvironment in a tightly defined junction between the specialized osteoclast border membrane and the bone matrix, thus allowing the localized solubilization of bone matrix. This in turn facilitates the proteolysis of demineralized bone collagen. Matrix degradation is thought to release matrix-associated growth factor and cytokines, which recruit osteoblasts in a temporally and spatially controlled fashion. Osteoblasts synthesize and secrete new bone matrix proteins, and subsequently mineralize this new matrix. In the normal skeleton this is a physiological process which does not result in a net change in bone mass. In pathological states, such as osteoporosis, the balance between resorption and formation is altered such that bone loss occurs.

The osteoclast itself is the direct or indirect target of all currently available osteoporosis agents with the possible exception of fluoride. Antiresorptive therapy prevents further bone loss in treated individuals. Osteoblasts are derived from multipotent stem cells which reside in bone marrow and also give rise to adipocytes, chondrocytes, fibroblasts and muscle cells. Selective enhancement of osteoblast activity is a highly desirable goal for osteoporosis therapy since it would result in an increase in bone mass, rather than a prevention of further bone loss. An effective

anabolic therapy would be expected to lead to a significantly greater reduction in fracture risk than currently available treatments.

5 The agonists or antagonists to the newly discovered polypeptides may act as antiresorptive by directly altering the osteoclast differentiation, osteoclast adhesion to the bone matrix or osteoclast function of degrading the bone matrix. The agonists or antagonists could indirectly alter the osteoclast function by interfering in the synthesis and/or modification of effector molecules of osteoclast differentiation or function such as cytokines, peptide or steroid hormones, proteases, etc.

10

The agonists or antagonists to the newly discovered polypeptides may act as anabolics by directly enhancing the osteoblast differentiation and /or its bone matrix forming function. The agonists or antagonists could also indirectly alter the osteoblast function by enhancing the synthesis of growth factors, peptide or steroid hormones or decreasing the synthesis of inhibitory molecules.

15

The agonists and antagonists may be used to mimic, augment or inhibit the action of the newly discovered polypeptides which may be useful to treat osteoporosis, Paget's disease, degradation of bone implants particularly dental implants.

20

This invention further pertains to the use of novel agents identified by the screening assays described above. Accordingly, it is within the scope of this invention to use a test compound identified as described herein in an appropriate animal model. For example, an agent identified as described herein (*e.g.*, a modulating agent, an antisense nucleic acid molecule, a specific antibody, ribozyme, or a DA-like GPCR polypeptide binding molecule) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

25
30

A reagent which affects DA-like GPCR activity can be administered to a human cell, either *in vitro* or *in vivo*, to reduce DA-like GPCR activity. The reagent preferably binds to an expression product of a human DA-like GPCR gene. If the expression product is a protein, the reagent is preferably an antibody. For treatment of human cells *ex vivo*, an antibody can be added to a preparation of stem cells which have been removed from the body. The cells can then be replaced in the same or another human body, with or without clonal propagation, as is known in the art.

In one embodiment, the reagent is delivered using a liposome. Preferably, the liposome is stable in the animal into which it has been administered for at least about 30 minutes, more preferably for at least about 1 hour, and even more preferably for at least about 24 hours. A liposome comprises a lipid composition that is capable of targeting a reagent, particularly a polynucleotide, to a particular site in an animal, such as a human. Preferably, the lipid composition of the liposome is capable of targeting to a specific organ of an animal, such as the lung, liver, spleen, heart brain, lymph nodes, and skin.

A liposome useful in the present invention comprises a lipid composition that is capable of fusing with the plasma membrane of the targeted cell to deliver its contents to the cell. Preferably, the transfection efficiency of a liposome is about 0.5 μg of DNA per 16 nmole of liposome delivered to about 10^6 cells, more preferably about 1.0 μg of DNA per 16 nmole of liposome delivered to about 10^6 cells, and even more preferably about 2.0 μg of DNA per 16 nmol of liposome delivered to about 10^6 cells. Preferably, a liposome is between about 100 and 500 nm, more preferably between about 150 and 450 nm; and even more preferably between about 200 and 400 nm in diameter.

Suitable liposomes for use in the present invention include those liposomes standardly used in, for example, gene delivery methods known to those of skill in the art. More preferred liposomes include liposomes having a polycationic lipid

composition and/or liposomes having a cholesterol backbone conjugated to polyethylene glycol. Optionally, a liposome comprises a compound capable of targeting the liposome to a tumor cell, such as a tumor cell ligand exposed on the outer surface of the liposome.

5

Complexing a liposome with a reagent such as an antisense oligonucleotide or ribozyme can be achieved using methods which are standard in the art (see, for example, U.S. Patent 5,705,151). Preferably, from about 0.1 µg to about 10 µg of polynucleotide is combined with about 8 nmol of liposomes, more preferably from about 0.5 µg to about 5 µg of polynucleotides are combined with about 8 nmol liposomes, and even more preferably about 1.0 µg of polynucleotides is combined with about 8 nmol liposomes.

10

In another embodiment, antibodies can be delivered to specific tissues *in vivo* using receptor-mediated targeted delivery. Receptor-mediated DNA delivery techniques are taught in, for example, Findeis *et al.* *Trends in Biotechnol.* 11, 202-05 (1993); Chiou *et al.*, GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER (J.A. Wolff, ed.) (1994); Wu & Wu, *J. Biol. Chem.* 263, 621-24 (1988); Wu *et al.*, *J. Biol. Chem.* 269, 542-46 (1994); Zenke *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 87, 3655-59 (1990); Wu *et al.*, *J. Biol. Chem.* 266, 338-42 (1991).

15

20

Determination of a Therapeutically Effective Dose

The determination of a therapeutically effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient which increases or decreases DA-like GPCR activity relative to the DA-like GPCR activity which occurs in the absence of the therapeutically effective dose.

25

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The

30

animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

5 Therapeutic efficacy and toxicity, *e.g.*, ED_{50} (the dose therapeutically effective in 50% of the population) and LD_{50} (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD_{50}/ED_{50} .

10

Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED_{50} with
15 little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

20

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect. Factors which can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be
25 administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.

30

Normal dosage amounts can vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations

for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

5 If the reagent is a single-chain antibody, polynucleotides encoding the antibody can be constructed and introduced into a cell either *ex vivo* or *in vivo* using well-established techniques including, but not limited to, transferrin-polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, 10 protoplast fusion, viral infection, electroporation, "gene gun," and DEAE- or calcium phosphate-mediated transfection.

Effective *in vivo* dosages of an antibody are in the range of about 5 µg to about 50 µg/kg, about 50 µg to about 5 mg/kg, about 100 µg to about 500 µg/kg of patient 15 body weight, and about 200 to about 250 µg/kg of patient body weight. For administration of polynucleotides encoding single-chain antibodies, effective *in vivo* dosages are in the range of about 100 ng to about 200 ng, 500 ng to about 50 mg, about 1 µg to about 2 mg, about 5 µg to about 500 µg, and about 20 µg to about 100 µg of DNA.

20 If the expression product is mRNA, the reagent is preferably an antisense oligonucleotide or a ribozyme. Polynucleotides which express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described above.

25 Preferably, a reagent reduces expression of a DA-like GPCR gene or the activity of a DA-GPCR polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of expression of a DA-like GPCR gene or 30 the activity of a DA-like GPCR polypeptide can be assessed using methods well known in the art, such as hybridization of nucleotide probes to DA-like GPCR-

specific mRNA, quantitative RT-PCR, immunologic detection of a DA-like GPCR polypeptide, or measurement of DA-like GPCR activity.

5 In any of the embodiments described above, any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described
10 above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

Any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows,
15 horses, rabbits, monkeys, and most preferably, humans.

Diagnostic Methods

GPCRs also can be used in diagnostic assays for detecting diseases and abnormalities
20 or susceptibility to diseases and abnormalities related to the presence of mutations in the nucleic acid sequences which encode a GPCR. Such diseases, by way of example, are related to cell transformation, such as tumors and cancers, and various cardiovascular disorders, including hypertension and hypotension, as well as diseases arising from abnormal blood flow, abnormal angiotensin-induced aldosterone
25 secretion, and other abnormal control of fluid and electrolyte homeostasis.

Differences can be determined between the cDNA or genomic sequence encoding a GPCR in individuals afflicted with a disease and in normal individuals. If a mutation is observed in some or all of the afflicted individuals but not in normal individuals,
30 then the mutation is likely to be the causative agent of the disease.

Sequence differences between a reference gene and a gene having mutations can be revealed by the direct DNA sequencing method. In addition, cloned DNA segments can be employed as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. For example, a sequencing
5 primer can be used with a double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures using radiolabeled nucleotides or by automatic sequencing procedures using fluorescent tags.

10 Genetic testing based on DNA sequence differences can be carried out by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Small sequence deletions and insertions can be visualized, for example, by high resolution gel electrophoresis. DNA fragments of different sequences can be distinguished on denaturing formamide gradient gels in which the
15 mobilities of different DNA fragments are retarded in the gel at different positions according to their specific melting or partial melting temperatures (*see, e.g., Myers et al., Science 230, 1242, 1985*). Sequence changes at specific locations can also be revealed by nuclease protection assays, such as RNase and S 1 protection or the chemical cleavage method (*e.g., Cotton et al., Proc. Natl. Acad. Sci. USA 85, 4397-
20 4401, 1985*). Thus, the detection of a specific DNA sequence can be performed by methods such as hybridization, RNase protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes and Southern blotting of genomic DNA. In addition to direct methods such as gel-electrophoresis and DNA sequencing, mutations can also be detected by *in situ* analysis.

25 Altered levels of a GPCR also can be detected in various tissues. Assays used to detect levels of the receptor polypeptides in a body sample, such as blood or a tissue biopsy, derived from a host are well known to those of skill in the art and include radioimmunoassays, competitive binding assays, Western blot analysis, and ELISA
30 assays.

All patents and patent applications cited in this disclosure are expressly incorporated herein by reference. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided for purposes of illustration only and are not
5 intended to limit the scope of the invention.

EXAMPLE 1

Detection of dopamine-like GPCR activity

10

The polynucleotide of SEQ ID NO. 1 is inserted into the expression vector pCEV4 and the expression vector pCEV4-dopamine-like GPCR polypeptide obtained is transfected into human embryonic kidney 293 cells. The cells are scraped from a culture flask into 5 ml of Tris HCl, 5 mM EDTA, pH 7.5, and lysed by sonication.
15 Cell lysates are centrifuged at 1000 rpm for 5 minutes at 4 °C. The supernatant is centrifuged at 30,000 x g for 20 minutes at 4°C. The pellet is suspended in binding buffer containing 50 mM Tris HCl, 5 mM MgSO₄, 1 mM EDTA, 100 mM NaCl, pH 7.5, supplemented with 0.1 % BSA, 2 µg/ml aprotinin, 0.5 mg/ml leupeptin, and 10 µg/ml phosphoramidon. Optimal membrane suspension dilutions, defined as the
20 protein concentration required to bind less than 10 % of an added radioligand, i.e. ¹²⁵I-labeled dopamine, are added to 96-well polypropylene microtiter plates containing ligand, non-labeled peptides, and binding buffer to a final volume of 250 µl.

25 In equilibrium saturation binding assays, membrane preparations are incubated in the presence of increasing concentrations (0.1 nM to 4 nM) of ¹²⁵I ligand.

Binding reaction mixtures are incubated for one hour at 30°C. The reaction is stopped by filtration through GF/B filters treated with 0.5% polyethyleneimine, using
30 a cell harvester. Radioactivity is measured by scintillation counting, and data are

analyzed by a computerized non-linear regression program. Non-specific binding is defined as the amount of radioactivity remaining after incubation of membrane protein in the presence of 100 nM of unlabeled peptide. Protein concentration is measured by the Bradford method using Bio-Rad Reagent, with bovine serum albumin as a standard. The dopamine-like GPCR activity of the polypeptide comprising the amino acid sequence of SEQ ID NO. 2 is demonstrated

EXAMPLE 2

10 *Radioligand binding assays*

Human embryonic kidney 293 cells transfected with a polynucleotide which expresses human DA-like GPCR are scraped from a culture flask into 5 ml of Tris HCl, 5 mM EDTA, pH 7.5, and lysed by sonication. Cell lysates are centrifuged at 15 1000 rpm for 5 minutes at 4°C. The supernatant is centrifuged at 30,000 x g for 20 minutes at 4°C. The pellet is suspended in binding buffer containing 50 mM Tris HCl, 5 mM MgSO₄, 1 mM EDTA, 100 mM NaCl, pH 7.5, supplemented with 0.1 % BSA, 2 µg/ml aprotinin, 0.5 mg/ml leupeptin, and 10 µg/ml phosphoramidon. Optimal membrane suspension dilutions, defined as the protein concentration required to bind less than 10 % of the added radioligand, i.e. dopamine, are added to 20 96-well polypropylene microtiter plates containing ¹²⁵I-labeled ligand or test compound, non-labeled peptides, and binding buffer to a final volume of 250 µl.

In equilibrium saturation binding assays, membrane preparations are incubated in the presence of increasing concentrations (0.1 nM to 4 nM) of ¹²⁵I-labeled ligand or test 25 compound (specific activity 2200 Ci/mmol). The binding affinities of different test compounds are determined in equilibrium competition binding assays, using 0.1 nM ¹²⁵I- peptide in the presence of twelve different concentrations of each test compound.

Binding reaction mixtures are incubated for one hour at 30°C. The reaction is stopped by filtration through GF/B filters treated with 0.5% polyethyleneimine, using a cell harvester. Radioactivity is measured by scintillation counting, and data are analyzed by a computerized non-linear regression program.

5

Non-specific binding is defined as the amount of radioactivity remaining after incubation of membrane protein in the presence of 100 nM of unlabeled peptide. Protein concentration is measured by the Bradford method using Bio-Rad Reagent, with bovine serum albumin as a standard. A test compound which increases the radioactivity of membrane protein by at least 15% relative to radioactivity of membrane protein which was not incubated with a test compound is identified as a compound which binds to a human DA-like GPCR polypeptide.

10

EXAMPLE 3

15

Effect of a test compound on human DA-like GPCR -mediated cyclic AMP formation

20

Receptor-mediated inhibition of cAMP formation can be assayed in host cells which express human DA-like GPCR. Cells are plated in 96-well plates and incubated in Dulbecco's phosphate buffered saline (PBS) supplemented with 10 mM HEPES, 5 mM theophylline, 2 µg/ml aprotinin, 0.5 mg/ml leupeptin, and 10 µg/ml phosphoramidon for 20 minutes at 37°C in 5% CO₂. A test compound is added and incubated for an additional 10 minutes at 37°C. The medium is aspirated, and the reaction is stopped by the addition of 100 mM HCl. The plates are stored at 4°C for 15 minutes. cAMP content in the stopping solution is measured by radioimmunoassay.

25

Radioactivity is quantified using a gamma counter equipped with data reduction software. A test compound which decreases radioactivity of the contents of a well relative to radioactivity of the contents of a well in the absence of the test compound

30

is identified as a potential inhibitor of cAMP formation. A test compound which increases radioactivity of the contents of a well relative to radioactivity of the contents of a well in the absence of the test compound is identified as a potential enhancer of cAMP formation.

5

EXAMPLE 4

Effect of a test compound on the mobilization of intracellular calcium

10 Intracellular free calcium concentration can be measured by microspectrofluorometry using the fluorescent indicator dye Fura-2/AM (Bush *et al.*, *J. Neurochem.* 57, 562-74, 1991). Stably transfected cells are seeded onto a 35 mm culture dish containing a glass coverslip insert. Cells are washed with HBS, incubated with a test compound, and loaded with 100 μ l of Fura-2/AM (10 μ M) for 20-40 minutes. After washing
15 with HBS to remove the Fura-2/AM solution, cells are equilibrated in HBS for 10-20 minutes. Cells are then visualized under the 40X objective of a Leitz Fluovert FS microscope.

Fluorescence emission is determined at 510 nm, with excitation wavelengths
20 alternating between 340 nm and 380 nm. Raw fluorescence data are converted to calcium concentrations using standard calcium concentration curves and software analysis techniques. A test compound which increases the fluorescence by at least 15% relative to fluorescence in the absence of a test compound is identified as a compound which mobilizes intracellular calcium.

25

EXAMPLE 5

Effect of a test compound on phosphoinositide metabolism

Cells which stably express human DA-like GPCR cDNA are plated in 96-well plates and grown to confluence. The day before the assay, the growth medium is changed to 100 μ l of medium containing 1% serum and 0.5 β Ci 3 H-myoinositol. The plates are incubated overnight in a CO₂ incubator (5% CO₂ at 37°C). Immediately before the
5 assay, the medium is removed and replaced by 200 μ l of PBS containing 10 mM LiCl, and the cells are equilibrated with the new medium for 20 minutes. During this interval, cells also are equilibrated with antagonist, added as a 10 μ l aliquot of a 20-fold concentrated solution in PBS.

10 The 3 H-inositol phosphate accumulation from inositol phospholipid metabolism is started by adding 10 μ l of a solution containing a test compound. To the first well 10 μ l are added to measure basal accumulation. Eleven different concentrations of test compound are assayed in the following 11 wells of each plate row. All assays are performed in duplicate by repeating the same additions in two consecutive plate
15 rows.

The plates are incubated in a CO₂ incubator for one hour. The reaction is terminated by adding 15 μ l of 50% v/v trichloroacetic acid (TCA), followed by a 40 minute incubation at 4°C. After neutralizing TCA with 40 μ l of 1 M Tris, the content of the
20 wells is transferred to a Multiscreen HV filter plate (Millipore) containing Dowex AG1-X8 (200-400 mesh, formate form). The filter plates are prepared by adding 200 μ l of Dowex AG1-X8 suspension (50% v/v, water:resin) to each well. The filter plates are placed on a vacuum manifold to wash or elute the resin bed. Each well is washed 2 times with 200 μ l of water, followed by 2 x 200 μ l of 5 mM sodium
25 tetraborate/60 mM ammonium formate.

The 3 H-IPs are eluted into empty 96-well plates with 200 μ l of 1.2 M ammonium formate/0.1 formic acid. The content of the wells is added to 3 ml of scintillation cocktail, and radioactivity is determined by liquid scintillation counting.

EXAMPLE 6

Receptor Binding Methods

5 Standard Binding Assays. Binding assays are carried out in a binding buffer containing 50 mM HEPES, pH 7.4, 0.5% BSA, and 5 mM $MgCl_2$. The standard assay for radioligand binding to membrane fragments comprising DA-like GPCR polypeptides is carried out as follows in 96 well microtiter plates (e.g., Dynatech Immulon II Removawell plates). Radioligand is diluted in binding buffer+
10 PMSF/Baci to the desired cpm per 50 μ l, then 50 μ l aliquots are added to the wells. For non-specific binding samples, 5 μ l of 40 μ M cold ligand also is added per well. Binding is initiated by adding 150 μ l per well of membrane diluted to the desired concentration (10-30 μ g membrane protein/well) in binding buffer+ PMSF/Baci. Plates are then covered with Linbro mylar plate sealers (Flow Labs) and placed on a
15 Dynatech Microshaker II. Binding is allowed to proceed at room temperature for 1-2 hours and is stopped by centrifuging the plate for 15 minutes at 2,000 x g. The supernatants are decanted, and the membrane pellets are washed once by addition of 200 μ l of ice cold binding buffer, brief shaking, and recentrifugation. The individual
20 wells are placed in 12 x 75 mm tubes and counted in an LKB Gammamaster counter (78% efficiency). Specific binding by this method is identical to that measured when free ligand is removed by rapid (3-5 seconds) filtration and washing on polyethyleneimine-coated glass fiber filters.

Three variations of the standard binding assay are also used.

25

1. Competitive radioligand binding assays with a concentration range of cold ligand vs. 125 I-labeled ligand are carried out as described above with one modification. All dilutions of ligands being assayed are made in 40X PMSF/Baci to a concentration 40X the final concentration in the assay.
30 Samples of peptide (5 μ l each) are then added per microtiter well.

Membranes and radioligand are diluted in binding buffer without protease inhibitors. Radioligand is added and mixed with cold ligand, and then binding is initiated by addition of membranes.

- 5 2. Chemical cross-linking of radioligand with receptor is done after a binding step identical to the standard assay. However, the wash step is done with binding buffer minus BSA to reduce the possibility of non-specific cross-linking of radioligand with BSA. The cross-linking step is carried out as described below.
- 10 3. Larger scale binding assays to obtain membrane pellets for studies on solubilization of receptor:ligand complex and for receptor purification are also carried out. These are identical to the standard assays except that (a)
- 15 binding is carried out in polypropylene tubes in volumes from 1-250 ml, (b) concentration of membrane protein is always 0.5 mg/ml, and (c) for receptor purification, BSA concentration in the binding buffer is reduced to 0.25%, and the wash step is done with binding buffer without BSA, which reduces BSA contamination of the purified receptor.

20 EXAMPLE 7

Chemical Cross-Linking of Radioligand to Receptor

After a radioligand binding step as described above, membrane pellets are resuspended in 200 µl per microtiter plate well of ice-cold binding buffer without BSA. Then 5 µl per well of 4 mM N-5-azido-2-nitrobenzoyloxysuccinimide (ANB-NOS, Pierce) in DMSO is added and mixed. The samples are held on ice and UV-irradiated for 10 minutes with a Mineralight R-52G lamp (UVP Inc., San Gabriel, Calif.) at a distance of 5-10 cm. Then the samples are transferred to Eppendorf microfuge tubes, the membranes pelleted by centrifugation, supernatants removed,

and membranes solubilized in Laemmli SDS sample buffer for polyacrylamide gel electrophoresis (PAGE). PAGE is carried out as described below. Radiolabeled proteins are visualized by autoradiography of the dried gels with Kodak XAR film and DuPont image intensifier screens.

5

EXAMPLE 8

Membrane Solubilization

10 Membrane solubilization is carried out in buffer containing 25 mM Tris , pH 8, 10% glycerol (w/v) and 0.2 mM CaCl_2 (solubilization buffer). The highly soluble detergents including Triton X-100, deoxycholate, deoxycholate:lysolecithin, CHAPS, and zwittergent are made up in solubilization buffer at 10% concentrations and stored as frozen aliquots. Lysolecithin is made up fresh because of insolubility upon freeze-
15 thawing and digitonin is made fresh at lower concentrations due to its more limited solubility.

To solubilize membranes, washed pellets after the binding step are resuspended free of visible particles by pipetting and vortexing in solubilization buffer at 100,000 x g
20 for 30 minutes. The supernatants are removed and held on ice and the pellets are discarded.

EXAMPLE 9

25 *Assay of Solubilized Receptors*

After binding of ^{125}I ligands and solubilization of the membranes with detergent, the intact R:L complex can be assayed by four different methods. All are carried out on ice or in a cold room at 4-10°C.).

30

1. Column chromatography (Knuhtsen *et al.*, *Biochem. J.* 254, 641-647, 1988).
Sephadex G-50 columns (8 x 250 mm) are equilibrated with solubilization
buffer containing detergent at the concentration used to solubilize membranes
and 1 mg/ml bovine serum albumin. Samples of solubilized membranes (0.2-
5 0.5 ml) are applied to the columns and eluted at a flow rate of about
0.7 ml/minute. Samples (0.18 ml) are collected. Radioactivity is determined
in a gamma counter. Void volumes of the columns are determined by the
elution volume of blue dextran. Radioactivity eluting in the void volume is
considered bound to protein. Radioactivity eluting later, at the same volume
10 as free ^{125}I ligands, is considered non-bound.
2. Polyethyleneglycol precipitation (Cuatrecasas, *Proc. Natl. Acad. Sci. USA* 69,
318-322, 1972). For a 100 μl sample of solubilized membranes in a 12 x 75
mm polypropylene tube, 0.5 ml of 1% (w/v) bovine gamma globulin (Sigma)
15 in 0.1 M sodium phosphate buffer is added, followed by 0.5 ml of 25% (w/v)
polyethyleneglycol (Sigma) and mixing. The mixture is held on ice for 15
minutes. Then 3 ml of 0.1 M sodium phosphate, pH 7.4, is added per sample.
The samples are rapidly (1-3 seconds) filtered over Whatman GF/B glass
fiber filters and washed with 4 ml of the phosphate buffer. PEG-precipitated
20 receptor : ^{125}I -ligand complex is determined by gamma counting of the filters.
3. GFB/PEI filter binding (Bruns *et al.*, *Analytical Biochem.* 132, 74-81, 1983).
Whatman GF/B glass fiber filters are soaked in 0.3% polyethyleneimine (PEI,
Sigma) for 3 hours. Samples of solubilized membranes (25-100 μl) are
25 replaced in 12 x 75 mm polypropylene tubes. Then 4 ml of solubilization
buffer without detergent is added per sample and the samples are immediately
filtered through the GFB/PEI filters (1-3 seconds) and washed with 4 ml of
solubilization buffer. CPM of receptor : ^{125}I -ligand complex adsorbed to
30 filters are determined by gamma counting.

4. Charcoal/Dextran (Paul and Said, *Peptides 7*[Suppl. 1],147-149, 1986). Dextran T70 (0.5 g, Pharmacia) is dissolved in 1 liter of water, then 5 g of activated charcoal (Norit A, alkaline; Fisher Scientific) is added. The suspension is stirred for 10 minutes at room temperature and then stored at 4°C. until use. To measure R:L complex, 4 parts by volume of charcoal/-
5 dextran suspension are added to 1 part by volume of solubilized membrane. The samples are mixed and held on ice for 2 minutes and then centrifuged for 2 minutes at 11,000 x g in a Beckman microfuge. Free radioligand is adsorbed charcoal/dextran and is discarded with the pellet. Receptor : ¹²⁵I-
10 ligand complexes remain in the supernatant and are determined by gamma counting.

EXAMPLE 10

15 *Receptor Purification*

Binding of biotinyl-receptor to GH₄ C1 membranes is carried out as described above. Incubations are for 1 hour at room temperature. In the standard purification protocol, the binding incubations contain 10 nM Bio-S29. ¹²⁵I ligand is added as a tracer at
20 levels of 5,000-100,000 cpm per mg of membrane protein. Control incubations contain 10 μM cold ligand to saturate the receptor with non-biotinylated ligand.

Solubilization of receptor:ligand complex also is carried out as described above, with 0.15% deoxycholate:lyssolecithin in solubilization buffer containing 0.2 mM MgCl₂,
25 to obtain 100,000 x g supernatants containing solubilized R:L complex.

Immobilized streptavidin (streptavidin cross-linked to 6% beaded agarose, Pierce Chemical Co.; "SA-agarose") is washed in solubilization buffer and added to the solubilized membranes as 1/30 of the final volume. This mixture is incubated with
30 constant stirring by end-over-end rotation for 4-5 hours at 4-10 °C. Then the mixture

is applied to a column and the non-bound material is washed through. Binding of radioligand to SA-agarose is determined by comparing cpm in the 100,000 x g supernatant with that in the column effluent after adsorption to SA-agarose. Finally, the column is washed with 12-15 column volumes of solubilization buffer+0.15% deoxycholate:lysolecithin +1/500 (vol/vol) 100 x 4pase.

The streptavidin column is eluted with solubilization buffer+0.1 mM EDTA+0.1 mM EGTA+0.1 mM GTP-gamma-S (Sigma)+0.15% (wt/vol) deoxycholate:lysolecithin +1/1000 (vol/vol) 100.times.4pase. First, one column volume of elution buffer is passed through the column and flow is stopped for 20-30 minutes. Then 3-4 more column volumes of elution buffer are passed through. All the eluates are pooled.

Eluates from the streptavidin column are incubated overnight (12-15 hours) with immobilized wheat germ agglutinin (WGA agarose, Vector Labs) to adsorb the receptor via interaction of covalently bound carbohydrate with the WGA lectin. The ratio (vol/vol) of WGA-agarose to streptavidin column eluate is generally 1:400. A range from 1:1000 to 1:200 also can be used. After the binding step, the resin is pelleted by centrifugation, the supernatant is removed and saved, and the resin is washed 3 times (about 2 minutes each) in buffer containing 50 mM HEPES, pH 8, 5 mM MgCl₂, and 0.15% deoxycholate:lysolecithin. To elute the WGA-bound receptor, the resin is extracted three times by repeated mixing (vortex mixer on low speed) over a 15-30 minute period on ice, with 3 resin columns each time, of 10 mM N-N'-N"-triacetylchitotriose in the same HEPES buffer used to wash the resin. After each elution step, the resin is centrifuged down and the supernatant is carefully removed, free of WGA-agarose pellets. The three, pooled eluates contain the final, purified receptor. The material non-bound to WGA contain G protein subunits specifically eluted from the streptavidin column, as well as non-specific contaminants. All these fractions are stored frozen at -90°C.

EXAMPLE 11*Identification of test compounds that bind to DA-like GPCR polypeptides*

5 Purified DA-GPCR polypeptides comprising a glutathione-S-transferase protein and absorbed onto glutathione-derivatized wells of 96-well microtiter plates are contacted with test compounds from a small molecule library at pH 7.0 in a physiological buffer solution. DA-GPCR polypeptides comprise an amino acid sequence shown in SEQ ID NO. 2. The test compounds comprise a fluorescent tag. The samples are
10 incubated for 5 minutes to one hour. Control samples are incubated in the absence of a test compound.

The buffer solution containing the test compounds is washed from the wells. Binding of a test compound to a DA-like GPCR polypeptide is detected by
15 fluorescence measurements of the contents of the wells. A test compound which increases the fluorescence in a well by at least 15% relative to fluorescence of a well in which a test compound is not incubated is identified as a compound which binds to a DA-like GPCR polypeptide.

20 EXAMPLE 12

Identification of a test compound which decreases DA-like GPCR gene expression

A test compound is administered to a culture of human gastric cells and incubated at
25 37°C for 10 to 45 minutes. A culture of the same type of cells incubated for the same time without the test compound provides a negative control.

RNA is isolated from the two cultures as described in Chirgwin *et al.*, *Biochem. 18*, 5294-99, 1979). Northern blots are prepared using 20 to 30 µg total RNA and
30 hybridized with a ³²P-labeled DA-like GPCR-specific probe at 65° C in Express-hyb

(CLONTECH). The probe comprises at least 11 contiguous nucleotides selected from the complement of SEQ ID NO. 1. A test compound which decreases the DA-like GPCR- specific signal relative to the signal obtained in the absence of the test compound is identified as an inhibitor of DA-like GPCR gene expression.

5

EXAMPLE 13

Treatment of schizophrenia with a reagent which specifically binds to a DA-like GPCR gene product

10

Synthesis of antisense DA-like GPCR oligonucleotides comprising at least 11 contiguous nucleotides selected from the complement of SEQ ID NO. 1 is performed on a Pharmacia Gene Assembler series synthesizer using the phosphoramidite procedure (Uhlmann *et al.*, *Chem. Rev.* 90, 534-83, 1990). Following assembly and deprotection, oligonucleotides are ethanol-precipitated twice, dried, and suspended in phosphate-buffered saline (PBS) at the desired concentration. Purity of these oligonucleotides is tested by capillary gel electrophoreses and ion exchange HPLC. Endotoxin levels in the oligonucleotide preparation are determined using the *Limulus* Amebocyte Assay (Bang, *Biol. Bull. (Woods Hole, Mass.)* 105, 361-362, 1953).

15

The antisense oligonucleotides are administered to a patient with schizophrenia. The severity of the patient's schizophrenia is lessened.

EXAMPLE 14

20

Ligand Binding Analysis

COS-7 cells are harvested 48 to 72 hr after transfection with human DA-like GPCR expression constructs. Cells contained in culture flasks (75 cm²) are rinsed with 5 ml of lysis buffer (10 mM Tris-HCl, 5 mM EDTA, pH 7.4). Cells are then scraped and homogenized in lysis buffer for 15 seconds using a Brinkman homogenizer.

25

30

Membranes are centrifuged at 50,000 x g for 20 minutes, and the pellet is resuspended in binding buffer (50 mM Tris HCl, 100 mM NaCl, 5 mM EDTA, pH 7.4). Saturation binding studies are performed with increasing concentrations of [¹²⁵I]SCH 23982 (2200 Ci/mmol; 1 Ci=37 GBq). Competition curves are performed with increasing concentrations of unlabeled drug under study against a constant concentration of [¹²⁵I]SCH 233982 (approximately 0.20 nM). The reaction is initiated by adding 100 µl of membranes (approximately 0.45 µg protein), and the assay mixture is incubated in a final volume of 200 µl for 1 hour at room temperature. Assay mixtures are then vacuum-filtered through Whatman GF/C glassfiber filters and washed 3 times with 5 ml of cold washing buffer (50 mM Tris HCl, 100 mM NaCl, pH 7.2). Total and nonspecific binding are delineated in the absence and presence of 10 µM cis-flupentixol. Each determination is done in triplicate. Bound radioactivity is measured at an efficiency of 75% using a gamma counter (LKB instruments). Binding curves are analyzed using non-linear multiple regression programs. See DeLean *et al.*, *Mol. Pharmacol.* 21, 5-16 (1982); McPherson, *J. Pharmacol. Methods* 14, 213-228 (1985).

Cis-flupentixol, cis-piflutixol, cis-teflutixol can be obtained from Lundbeck (Denmark). Fluperlapine can be obtained from Novo Nordisk (Bagsvaerd, Denmark). SCH 23388 AND SCH 23390 can be obtained from Schering Plough (Bloomfield, N.J.). Apomorphine, (+)butaclamol, dopamine hydrochloride, haloperidol, R(-)- propylnorapomorphine (NPA) and spiperone can be purchased from Research Biochemical Industries (RBI). Fenoldopam and SKF 38393 can be obtained from Smith, Kline & French. [¹²⁵I]SCH 23982 was from New England Nuclear Boston, Mass.).

EXAMPLE 15*Tissue-specific expression of Dopamine-like GPCR*

5 The expression profiling of the Dopamine-like GPCR by real-time quantitative PCR with RNA samples from human tissue establishes a role for the Dopamine-like GPCR in human disease. The panel consists of total RNA from brain, total Alzheimer brain, fetal brain, cerebellum, spinal cord, heart, fetal heart, pericardium, coronary smooth muscle cells, thyroid, thyroid tumor, spleen, spleen (from liver
10 cirrhosis patient), thymus, bone marrow, lung, fetal lung, lung tumor, liver, fetal liver, liver (from liver cirrhosis patient), pancreas, pancreas (from liver cirrhosis patient), stomach, small intestine, colon, colon tumor, kidney, skeletal muscle, HeLa cells, breast tumor, mammary gland, MDA MB 231 cells, testis, trachea, adrenal gland, salivary gland, bladder, prostata, placenta, uterus, adipose tissue. A
15 development of the kinetic analysis of PCR is described in Higuchi *et al.*, *BioTechnology* 10, 413-17, 1992, and Higuchi *et al.*, *BioTechnology* 11, 1026-30, 1993. The principle is that at any given cycle within the exponential phase of PCR, the amount of product is proportional to the initial number of template copies.

20 PCR amplification is performed in the presence of an oligonucleotide probe (TaqMan probe) that is complementary to the target sequence and labeled with a fluorescent reporter dye and a quencher dye. During the extension phase of PCR, the probe is cleaved by the 5'-3' endonuclease activity of Taq DNA polymerase, releasing the fluorophore from the effect of the quenching dye (Holland *et al.*, *Proc.*
25 *Natl. Acad. Sci. U.S.A.* 88, 7276-80, 1991). Because the fluorescence emission increases in direct proportion to the amount of the specific amplified product, the exponential growth phase of PCR product can be detected and used to determine the initial template concentration (Heid *et al.*, *Genome Res.* 6, 986-94, 1996, and Gibson *et al.*, *Genome Res.* 6, 995-1001, 1996).

30

Real-time quantitative PCR is done using an ABI Prism 7700 Sequence Detector.

The C_T value generated for each reaction is used to determine the initial template concentration (copy number) by interpolation from a universal standard curve. The level of expression of the target gene in each sample is calculated relative to the sample with the lowest expression of the gene.

5

RNA extraction and cDNA preparation. Total RNA from each of the cell types listed above were isolated using Qiagen's RNeasy system according to the manufacturer's protocol (Crawley, West Sussex, UK). The concentration of purified RNA is determined using a RiboGreen RNA quantitation kit (Molecular Probes Europe, The Netherlands). For the preparation of cDNA, 1 µg of total RNA is reverse transcribed in a final volume of 20 µl, using 200 U of SUPERScript™ RNase H⁻ Reverse Transcriptase (Life Technologies, Paisley, UK), 10 mM dithiothreitol, 0.5 mM of each dNTP and 5 µM random hexamers (Applied Biosystems, Warrington, Cheshire, UK) according to the manufacturer's protocol.

15

TaqMan quantitative analysis. Specific primers and probe were designed according to the recommendations of PE Applied Biosystems; a FAM (6-carboxy-fluorescein)-labeled probe is used. Quantification PCR is performed with 5 ng of reverse transcribed RNA from each sample. Each determination is done in duplicate.

20

The assay reaction mix is as follows: 1X final TaqMan Universal PCR Master Mix (from 2X stock) (PE Applied Biosystems, CA); 900 nM forward primer; 900 nM reverse primer; 200 nM probe; 5 ng cDNA; and water to 25 µl.

25

Each of the following steps were carried out once: pre PCR, 2 minutes at 50 °C, and 10 minutes at 95°C. The following steps are carried out 40 times: denaturation, 15 seconds at 95°C, annealing/extension, 1 minute at 60°C.

30

All experiments were performed using an ABI Prism 7700 Sequence Detector (PE Applied Biosystems, CA). At the end of the run, fluorescence data acquired during PCR were processed as described in the ABI Prism 7700 user's manual to achieve

better background subtraction as well as signal linearity with the starting target quantity.

5 Table 1 shows the results of expression profiling for Dopamine-like GPCR using the indicated cell and tissue samples. The result is shown graphically in Fig. 5. Relative high expression is detected in Alzheimer's brain compared to normal brain and in cancer tissue compared to the corresponding normal tissue.

Table 1:

10

	tissue	rel ex		tissue	rel ex
1.	brain	0,00	22.	pancreas	240,57
2.	total Alzheimer brain	379,60	23.	pancreas liver cirrhosis	14,47
3.	fetal brain	13,39	24.	stomach	160,85
4.	cerebellum	0,00	25.	small intestine	234,24
5.	spinal cord	2,52	26.	colon	56,98
6.	heart	0,00	27.	colon tumor	200,85
7.	fetal heart	1,14	28.	kidney	38,63
8.	pericardium	16,24	29.	skeletal muscle	144,79
9.	coronary smooth muscle cells	578,70	30.	HeLa cells	1,96
10.	thyroid	0,00	31.	breast tumor	300,25
11.	thyroid tumor	7,34	32.	mammary gland	17,44
12.	spleen	199,84	33.	MDA MB 231 cells	34,54
13.	spleen liver cirrhosis	1,00	34.	testis	124,01
14.	thymus	0,00	35.	trachea	0,00
15.	bone marrow	0,00	36.	adrenal gland	0,00
16.	lung	62,50	37.	salivary gland	0,00
17.	fetal lung	10,18	38.	bladder	0,00
18.	lung tumor	393,89	39.	prostata	10,37
19.	liver	60,83	40.	placenta	0,00
20.	fetal liver	636,96	41.	uterus	2499,15
21.	liver liver cirrhosis	628,89	42.	adipose	11,00

CLAIMS

1. An isolated polynucleotide encoding a dopamine-like GPCR polypeptide and being selected from the group consisting of:
- 5
- a) a polynucleotide encoding a dopamine-like GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:
- 10 amino acid sequences which are at least about 600% identical to the amino acid sequence shown in SEQ ID NO. 2; and the amino acid sequence shown in SEQ ID NO. 2.
- b) a polynucleotide comprising the sequence of SEQ ID NO. 1;
- 15 c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b);
- d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of
- 20 the genetic code; and
- e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d).
- 25 2. An expression vector containing any polynucleotide of claim 1.
3. A host cell containing the expression vector of claim 2.
4. A substantially purified dopamine-like GPCR polypeptide encoded by a
- 30 polynucleotide of claim 1.

5. A method for producing a dopamine-like GPCR polypeptide, wherein the method comprises the following steps:
- a) culturing the host cell of claim 3 under conditions suitable for the expression of the dopamine-like GPCR polypeptide; and
 - b) recovering the dopamine-like GPCR polypeptide from the host cell culture.
6. A method for detection of a polynucleotide encoding a dopamine-like GPCR polypeptide in a biological sample comprising the following steps:
- a) hybridizing any polynucleotide of claim 1 to a nucleic acid material of a biological sample, thereby forming a hybridization complex; and
 - b) detecting said hybridization complex.
7. The method of claim 6, wherein before hybridization, the nucleic acid material of the biological sample is amplified.
8. A method for the detection of a polynucleotide of claim 1 or a dopamine-like GPCR polypeptide of claim 4 comprising the steps of:
- contacting a biological sample with a reagent which specifically interacts with the polynucleotide or the dopamine-like GPCR polypeptide.
9. A diagnostic kit for conducting the method of any one of claims 6 to 8.
10. A method of screening for agents which decrease the activity of a dopamine-like GPCR, comprising the steps of:

contacting a test compound with any dopamine-like GPCR polypeptide encoded by any polynucleotide of claim 1;

5 detecting binding of the test compound to the dopamine-like GPCR polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential therapeutic agent for decreasing the activity of a dopamine-like GPCR.

10 11. A method of screening for agents which regulate the activity of a dopamine-like GPCR, comprising the steps of:

contacting a test compound with a dopamine-like GPCR polypeptide encoded by any polynucleotide of claim 1; and

15 detecting a dopamine-like GPCR activity of the polypeptide, wherein a test compound which increases the dopamine-like GPCR activity is identified as a potential therapeutic agent for increasing the activity of the dopamine-like GPCR, and wherein a test compound which decreases the dopamine-like GPCR activity of the polypeptide is identified as a potential therapeutic agent
20 for decreasing the activity of the dopamine-like GPCR.

12. A method of screening for agents which decrease the activity of a dopamine-like GPCR, comprising the steps of:

25 contacting a test compound with any polynucleotide of claim 1 and detecting binding of the test compound to the polynucleotide, wherein a test compound which binds to the polynucleotide is identified as a potential therapeutic agent for decreasing the activity of dopamine-like GPCR.

30 13. A method of reducing the activity of dopamine-like GPCR, comprising the steps of:

contacting a cell with a reagent which specifically binds to any polynucleotide of claim 1 or any dopamine-like GPCR polypeptide of claim 4, whereby the activity of dopamine-like GPCR is reduced.

5

14. A reagent that modulates the activity of a dopamine-like GPCR polypeptide or a polynucleotide wherein said reagent is identified by the method of any of the claim 10 to 12.

10

15. A pharmaceutical composition, comprising:

the expression vector of claim 2 or the reagent of claim 14 and a pharmaceutically acceptable carrier.

15

16. Use of the pharmaceutical composition of claim 15 for modulating the activity of a dopamine-like GPCR in a disease.

17. Use of claim 16 wherein the disease is obesity and disease related to obesity, cancer, diabetes, osteoporosis, anxiety, depression, hypertension, migraine, compulsive disorder, schizophrenia, autism, neurodegenerative disorder and cancer chemotherapy-induced vomiting.

20

18. A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2.

25

19. The cDNA of claim 18 which comprises of SEQ ID NO. 1.

20. The cDNA of claim 18 which consist of SEQ ID NO. 1.

30

21. An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2.

22. The expression vector of claim 21 wherein the polynucleotide consists of SEQ ID NO. 1.
- 5 23. A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2.
24. The host cell of claim 23 wherein the polynucleotide consists of SEQ ID NO. 1.
- 10 25. A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2.
- 15 26. The purified polypeptide of claim 25 which consists of the amino acid sequence shown in SEQ ID NO. 2.
27. A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO. 2.
- 20 28. A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, comprising the steps of:
- 25 culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed; and isolating the polypeptide.
29. The method of claim 28 wherein the expression vector comprises SEQ ID NO. 1.
- 30 30. A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, comprising the steps of:

hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO. 1 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and

5

detecting the hybridization complex.

31. The method of claim 30 further comprising the step of amplifying the nucleic acid material before the step of hybridizing.

10

32. A kit for detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, comprising:

a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO. 1; and

15

instructions for the method of claim 30.

33. A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, comprising the steps of:

20

contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex; and

detecting the reagent-polypeptide complex.

25

34. The method of claim 33 wherein the reagent is an antibody.

35. A kit for detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2 comprising:

30

an antibody which specifically binds to the polypeptide; and

instructions for the method of claim 33.

5 36. A method of screening for agents which can regulate the activity of a dopamine-like GPCR protein, comprising the steps of:

contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of: (1) amino acid sequences which are at least about 60% identical to the amino acid sequence shown in
10 SEQ ID NO. 2 and (2) the amino acid sequence shown in SEQ ID NO. 2 ; and

detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential agent for regulating activity of the dopamine-like GPCR protein.

15 37. The method of claim 36 wherein the step of contacting is in a cell.

38. The method of claim 36 wherein the cell is in vitro.

20 39. The method of claim 36 wherein the step of contacting is in a cell-free system.

40. The method of claim 36 wherein the polypeptide comprises a detectable label.

25 41. The method of claim 36 wherein the test compound comprises a detectable label.

42. The method of claim 36 wherein the test compound displaces a labeled ligand which is bound to the polypeptide.

30 43. The method of claim 36 wherein the polypeptide is bound to a solid support.

44. The method of claim 36 wherein the test compound is bound to a solid support.
- 5 45. A method of screening for agents which regulate an activity of a human dopamine-like GPCR protein, comprising the steps of:
- 10 contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of: (1) amino acid sequences which are at least about 60% identical to the amino acid sequence shown in SEQ ID NO. 2 and (2) the amino acid sequence shown in SEQ ID NO. 2; and
- 15 detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human dopamine-like GPCR protein, and wherein a test compound which decreases the activity of the polypeptide is identified as a potential agent for decreasing the activity of the human dopamine-like GPCR protein.
- 20 46. The method of claim 45 wherein the step of contacting is in a cell.
47. The method of claim 45 wherein the cell is in vitro.
48. The method of claim 45 wherein the step of contacting is in a cell-free system.
- 25 49. The method of claim 45 wherein the activity is cyclic AMP formation.
50. The method of claim 45 wherein the activity is mobilization of intracellular calcium.
- 30

51. The method of claim 45 wherein the activity is phosphoinositide metabolism.
52. A method of screening for agents which regulate an activity of a human dopamine-like GPCR protein, comprising the steps of:
- 5 contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NO. 1; and
- 10 detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human dopamine-like GPCR protein.
53. The method of claim 52 wherein the product is a polypeptide.
- 15 54. The method of claim 52 wherein the product is RNA.
55. A method of reducing activity of a human dopamine-like GPCR protein, comprising the step of:
- 20 contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO. 1, whereby the activity of a human dopamine-like GPCR protein is reduced.
- 25 56. The method of claim 55 wherein the product is a polypeptide.
57. The method of claim 56 wherein the reagent is an antibody.
58. The method of claim 55 wherein the product is RNA.
- 30 59. The method of claim 58 wherein the reagent is an antisense oligonucleotide.

60. The method of claim 58 wherein the reagent is a ribozyme.
61. The method of claim 55 wherein the cell is in vitro.
- 5 62. The method of claim 55 wherein the cell is in vitro.
63. A pharmaceutical composition, comprising :
a reagent which specifically binds to a polypeptide comprising the amino acid
10 sequence shown in SEQ ID NO. 2; and
a pharmaceutically acceptable carrier.
64. The pharmaceutical composition of claim 63 wherein the reagent is an
15 antibody.
65. A pharmaceutical composition, comprising:
a reagent which specifically binds to a product of a polynucleotide
20 comprising the nucleotide sequence shown in SEQ ID NO. 1; and
a pharmaceutically acceptable carrier.
66. The pharmaceutical composition of claim 65 wherein the reagent is a
25 ribozyme.
67. The pharmaceutical composition of claim 65 wherein the reagent is an
antisense oligonucleotide.
68. The pharmaceutical composition of claim 65 wherein the reagent is an
30 antibody.

69. A pharmaceutical composition, comprising :
- an expression vector encoding a polypeptide comprising the amino acid
sequence shown in SEQ ID NO. 2; and
- a pharmaceutically acceptable carrier.
70. The pharmaceutical composition of claim 69 wherein the expression vector
comprises SEQ ID NO. 1.
71. A method of treating dopamine-like GPCR disorder, comprising the step of:
- administering to a patient in need thereof a therapeutically effective dose of a
reagent that inhibits a function of a human dopamine-like GPCR protein,
whereby symptoms of the dopamine-like GPCR disorder are ameliorated.
72. The method of claim 71 wherein the reagent is identified by the method of
claim 36.
73. The method of claim 71 wherein the reagent is identified by the method of
claim 45.
74. The method of claim 71 wherein the reagent is identified by the method of
claim 52.
75. The method of claim 71 wherein the dopamine-like GPCR disorder is obesity
and disease related to obesity, cancer, diabetes, osteoporosis, anxiety,
depression, hypertension, migraine, compulsive disorder, schizophrenia,
autism, neurodegenerative disorder and cancer chemotherapy-induced
vomiting.

Fig. 1

atggaatcat ctttctcatt tggagtgate cttgctgtcc tggcctccct
 catcattgct actaacacac tagtggctgt ggctgtgctg ctgttgatcc
 acaagaatga tgggtgtcagt ctctgcttca ccttgaatct ggctgtggct
 gacaccttga ttgggtgtggc catctctggc ctactcacag accagctctc
 cagcccttct cggcccacac agaagaccct gtgcagcctg cggatggcat
 ttgtcacttc ctccgcagct gcctctgtcc tcacggtcac gctgatcacc
 tttgacaggt accttgccat caagcagccc ttccgctact tgaagatcat
 gagtgggttc gtggccgggg cctgcattgc cgggctgtgg ttagtgtctt
 acctcattgg cttcctccca ctcggaatcc ccatgttcca gcagactgcc
 tacaaagggc agtgcagctt ctttgctgta tttcaccttc acttcgtgct
 gacctctctc tgcgttggct tcttcccagc catgctcctc tttgtcttct
 tctactgcga catgctcaag attgcctcca tgcacagcca gcagattcga
 aagatggaac atgcaggagc catggctgga ggttatcgat cccacaggac
 tcccagcgac ttcaaagctc tccgtactgt gtctgttctc attgggagct
 ttgctctatc ctggaccccc ttccttatca ctggcattgt gcaggtggcc
 tgccaggagt gtcacctcta cctagtgtgt gaacgggtacc tgtggctgtc
 cggcgtgggc aactccctgc tcaaccact catctatgcc tattggcaga
 aggaggtgcy actgcagctc taccacatgg ccctaggagt gaagaagggtg
 ctcacctcat tcctcctctt tctctcggcc aggaattgtg gccagagag
 gccagggaa agttcctgtc acatcgtcac tatctccagc tcagagtttg
 atggctaa

Fig. 2

MESSFSFGVILAVLASLI IATNTLVAVAVLLLIHKNDGVSLCFTLNLA
 DTLIGVAISGLLTDQLSSPSRPTQKTLCSLRMAFVTSSAAASVLTVM
 LITFDRYLAIKQPPRYLKIMSGFVAGACIAGLWLVSYLIGFLPLGIPMFQQT
 AYKGQCSFFAVFHPHFVLTLSCVGFFPAMLLFVFFYCDMLKIASMHSQQIR
 KMEHAGAMAGGYRSPRTPSDFKALRTVSVLIGSFALSWTPFLITGIVQVA
 CQECHLYLVLERYLWLLGVGNSLLNPLIYAYWQKEVRLQLYHMALGVKKV
 LTSFLLFLSARNCGPERPRESSCHIVTISSEFDG*

Fig. 3

MYTPHPFGFL IILVPMTNAM RAIAAIAAGV GSVAATVATS TTSSISSSTT
IINTSSATTI GGNHTSGSTG FSTNSTLLDA DHLPLQLTTA KVDLDIEIDI
QLLTNGYDGT TLTSFYNESS WTNASEMDTI VGEEPEPLSL VSIVVVGIFL
SVLIFLSVAG NILVCLAIYT DGSLPRIGNL FLASLAIADL FVASLVMTFA
GVNDLLGYWI FGAQFCDTWV AFDVMCSTAS ILNLCAISM DRYIHIKDPLR
YGRWVTRRVA VITIAAIWLL AAFVSFVPIS LGIHRPDQPL IFEDNGKKYP
TCALDLTPTY AVVSSCISFY FPCVVMIGIY CRLYCYAQKH VKSIKAVTRP
GEVAEKQRYK SIRRPKNQPK KFKVRNLHTH SSPYHVSDHK AAVTVGVIMG
VFLICWVPFF CVNITAAFCK SDRFITDYAA KNVVVMNSGR SSAELEQVSA I

Fig. 4

BLASTX - alignment of 115 against swiss|P41596|DOP1_DROME
 DOPAMINE RECEPTOR 1 PRECURSOR (D-DOP1).//:trembl|x77234|DMDOPREC_1 product:
 "dopamine receptor"; D.melanogaster mRNA
 for dopamine receptor //:gp|x77234|479128 product: "dopamine receptor";
 D.melanogaster mRNA for dopamine receptor.

This hit is scoring at : 9e-25 (expectation value)

Alignment length (overlap) : 350

Identities : 30 %

Scoring matrix : BLOSUM62 (used to infer consensus pattern)

Query reading frame : +1

Database searched : nrdb

Q: 22 GVILAVLASLIATNTLVAVAVLLLIHKNDG----VSLCFTLNLAADTLIGVAISGL-
 G:.L:VL. L :A N.LV:A:.. .DG :..F:..LA:AD:.. :..
 H: 147 GIFLSVLIFLSVAGNILVCLAY----TDGSLPRIGNLFLASLAIAADLFVASLVMTFAG

LTDQLSSPSRPTQKTLCSLRMAFVTSSAAASVLTVMELITFDRLAIAKQPFYLYKIMSGFV
 :.D L. .Q .C.. :AF ...:AS:L:...I:.DRY: IK.P.RY : : V
VNDLLGYWIFGAQûFCDTWVAFDVCMCSTASILNLCAISMDRYIHKDLRYGRWVTRRV

AGACIAGLWLVSYLIGFLPLGI-----PMFQQTAYKGQCSCFFAVFHPHFVITLSCVGF
 A ..IA.:WL:..:F:P:.. P:.. K.:. P :... SC:.F
AVITIAAIWLLAAAFVSFVPISLGIHRPDQPLIFEDNGKKYPTCALDLTPTYAVVSSCISF


FPAMLLFVFFYCDMLKIASMHSQQIRKMEHAGAMA--GGYRSRPTP-----
 :YC :. .A..H :I:.....G:A Y:S R.P

YFPCVVMIGIYCRLYCYAQKHVKSIKAVTRPGEVAEKQRYKSIRRPKNQPKFKVVRNLHT

-----SDFKALRTVSVLIGSFALSWTPFLITGIVQVACQECHLYLVLERYLWLLGVGN
SD.KA. TV.V::G F::W.PF...I... C::C ...:..W LG..N
HSSPYHVS~~HDHKA~~AVTVGVIMGVFLICWVPFFFCVNITAAFCCTCIGGGQTFKILTW-LGYSN

SLLNPLIYAYWQKEVRLQLYHMALGVKKVLTSLFLSARNCGPERPRES	963
S..NP:IY::..KE.R ..K::LT. :..A:::G .PR.S	
<u>SAFNPIIYSIENKEFR</u> -----DAFKRILTMRNPNPWCCAQDVGNIHPRNS	481

Fig. 5:



SEQUENCE LISTING

<110> Bayer AG

<120> REGULATION OF HUMAN DOPAMINE-LIKE
G PROTEIN-COUPLED RECEPTOR

<130> REGULATION OF HUMAN DOPAMINE-LIKE

<140>

<141>

<150> 60/205,195

<151> 2000-05-18

<160> 3

<170> PatentIn Ver. 2.0

<210> 1

<211> 1008

<212> DNA

<213> Human

<400> 1

```

atggaatcat ctttctcatt tggagtgatc cttgctgtcc tggcctccct catcattgct 60
actaacacac tagtggctgt ggctgtgctg ctggtgatcc acaagaatga tgggtgcagt 120
ctctgcttca ccttgaatct ggctgtggct gacaccttga ttggtgtggc catctctggc 180
ctactcacag accagctctc cagcccttct cggccacac agaagaccct gtgcagcctg 240
cggatggcat ttgtcacttc ctccgcagct gcctctgtcc tcacgggtcat gctgatcacc 300
tttgacaggt accttgccat caagcagccc ttccgctact tgaagatcat gagtgggttc 360
gtggcgggg cctgcattgc cgggctgtgg ttagtgtctt acctcattgg cttcctccca 420
ctcggaatcc ccatgttcca gcagactgcc tacaaggggc agtgcagctt ctttgcgtga 480
tttcaccctc acttcgtgct gacctctcc tgcgttggct tcttccagc catgctcctc 540
tttgtcttct tctactgca catgctcaag attgcctcca tgcacagcca gcagattcga 600
aagatggaac atgcaggagc catggctgga gggtatcgat cccacggac tcccagcgac 660
ttcaaagctc tccgtactgt gtctgttctc attgggagct ttgctctatc ctggaccccc 720
ttccttatca ctggcattgt gcaggtggcc tgccaggagt gtcacctcta cctagtgtg 780
gaacggtaac tgtggctgct cggcgtgggc aactccctgc tcaaccact catctatgcc 840
tattggcaga aggaggtgcg actgcagctc taccacatgg ccctaggagt gaagaagggtg 900
ctcacctcat tcctcctctt tctctcggcc aggaattgtg gccagagag gccagggaa 960
agttcctgtc acatcgtcac tatctccagc tcagagtttg atggctaa 1008

```

<210> 2

<211> 335

<212> PRT

<213> Human

<400> 2

```

Met Glu Ser Ser Phe Ser Phe Gly Val Ile Leu Ala Val Leu Ala Ser
 1              5              10              15

Leu Ile Ile Ala Thr Asn Thr Leu Val Ala Val Ala Val Leu Leu Leu
      20              25              30

Ile His Lys Asn Asp Gly Val Ser Leu Cys Phe Thr Leu Asn Leu Ala
      35              40              45

Val Ala Asp Thr Leu Ile Gly Val Ala Ile Ser Gly Leu Leu Thr Asp
      50              55              60

Gln Leu Ser Ser Pro Ser Arg Pro Thr Gln Lys Thr Leu Cys Ser Leu
 65              70              75              80

Arg Met Ala Phe Val Thr Ser Ser Ala Ala Ala Ser Val Leu Thr Val
      85              90              95

Met Leu Ile Thr Phe Asp Arg Tyr Leu Ala Ile Lys Gln Pro Phe Arg
      100              105              110

Tyr Leu Lys Ile Met Ser Gly Phe Val Ala Gly Ala Cys Ile Ala Gly
      115              120              125

Leu Trp Leu Val Ser Tyr Leu Ile Gly Phe Leu Pro Leu Gly Ile Pro
      130              135              140

Met Phe Gln Gln Thr Ala Tyr Lys Gly Gln Cys Ser Phe Phe Ala Val
      145              150              155              160

Phe His Pro His Phe Val Leu Thr Leu Ser Cys Val Gly Phe Phe Pro
      165              170              175

Ala Met Leu Leu Phe Val Phe Phe Tyr Cys Asp Met Leu Lys Ile Ala
      180              185              190

Ser Met His Ser Gln Gln Ile Arg Lys Met Glu His Ala Gly Ala Met
      195              200              205

Ala Gly Gly Tyr Arg Ser Pro Arg Thr Pro Ser Asp Phe Lys Ala Leu
      210              215              220

Arg Thr Val Ser Val Leu Ile Gly Ser Phe Ala Leu Ser Trp Thr Pro
      225              230              235              240

Phe Leu Ile Thr Gly Ile Val Gln Val Ala Cys Gln Glu Cys His Leu
      245              250              255

```

Tyr Leu Val Leu Glu Arg Tyr Leu Trp Leu Leu Gly Val Gly Asn Ser
 260 265 270

Leu Leu Asn Pro Leu Ile Tyr Ala Tyr Trp Gln Lys Glu Val Arg Leu
 275 280 285

Gln Leu Tyr His Met Ala Leu Gly Val Lys Lys Val Leu Thr Ser Phe
 290 295 300

Leu Leu Phe Leu Ser Ala Arg Asn Cys Gly Pro Glu Arg Pro Arg Glu
 305 310 315 320

Ser Ser Cys His Ile Val Thr Ile Ser Ser Ser Glu Phe Asp Gly
 325 330 335

<210> 3

<211> 451

<212> PRT

<213> Human

<400> 3

Met Tyr Thr Pro His Pro Phe Gly Phe Leu Ile Ile Leu Val Pro Met
 1 5 10 15

Thr Asn Ala Met Arg Ala Ile Ala Ala Ile Ala Ala Gly Val Gly Ser
 20 25 30

Val Ala Ala Thr Val Ala Thr Ser Thr Thr Ser Ser Ile Ser Ser Ser
 35 40 45

Thr Thr Ile Ile Asn Thr Ser Ser Ala Thr Thr Ile Gly Gly Asn His
 50 55 60

Thr Ser Gly Ser Thr Gly Phe Ser Thr Asn Ser Thr Leu Leu Asp Ala
 65 70 75 80

Asp His Leu Pro Leu Gln Leu Thr Thr Ala Lys Val Asp Leu Asp Ile
 85 90 95

Glu Ile Asp Ile Gln Leu Leu Thr Asn Gly Tyr Asp Gly Thr Thr Leu
 100 105 110

Thr Ser Phe Tyr Asn Glu Ser Ser Trp Thr Asn Ala Ser Glu Met Asp
 115 120 125

Thr Ile Val Gly Glu Glu Pro Glu Pro Leu Ser Leu Val Ser Ile Val

130	135	140																	
Val	Val	Gly	Ile	Phe	Leu	Ser	Val	Leu	Ile	Phe	Leu	Ser	Val	Ala	Gly				
145					150					155					160				
Asn	Ile	Leu	Val	Cys	Leu	Ala	Ile	Tyr	Thr	Asp	Gly	Ser	Leu	Pro	Arg				
				165					170						175				
Ile	Gly	Asn	Leu	Phe	Leu	Ala	Ser	Leu	Ala	Ile	Ala	Asp	Leu	Phe	Val				
			180					185						190					
Ala	Ser	Leu	Val	Met	Thr	Phe	Ala	Gly	Val	Asn	Asp	Leu	Leu	Gly	Tyr				
		195					200					205							
Trp	Ile	Phe	Gly	Ala	Gln	Phe	Cys	Asp	Thr	Trp	Val	Ala	Phe	Asp	Val				
210					215						220								
Met	Cys	Ser	Thr	Ala	Ser	Ile	Leu	Asn	Leu	Cys	Ala	Ile	Ser	Met	Asp				
225					230					235					240				
Arg	Tyr	Ile	His	Ile	Lys	Asp	Pro	Leu	Arg	Tyr	Gly	Arg	Trp	Val	Thr				
			245						250						255				
Arg	Arg	Val	Ala	Val	Ile	Thr	Ile	Ala	Ala	Ile	Trp	Leu	Leu	Ala	Ala				
		260						265						270					
Phe	Val	Ser	Phe	Val	Pro	Ile	Ser	Leu	Gly	Ile	His	Arg	Pro	Asp	Gln				
		275					280					285							
Pro	Leu	Ile	Phe	Glu	Asp	Asn	Gly	Lys	Lys	Tyr	Pro	Thr	Cys	Ala	Leu				
		290				295					300								
Asp	Leu	Thr	Pro	Thr	Tyr	Ala	Val	Val	Ser	Ser	Cys	Ile	Ser	Phe	Tyr				
305					310					315					320				
Phe	Pro	Cys	Val	Val	Met	Ile	Gly	Ile	Tyr	Cys	Arg	Leu	Tyr	Cys	Tyr				
			325						330					335					
Ala	Gln	Lys	His	Val	Lys	Ser	Ile	Lys	Ala	Val	Thr	Arg	Pro	Gly	Glu				
			340					345						350					
Val	Ala	Glu	Lys	Gln	Arg	Tyr	Lys	Ser	Ile	Arg	Arg	Pro	Lys	Asn	Gln				
		355					360						365						
Pro	Lys	Lys	Phe	Lys	Val	Arg	Asn	Leu	His	Thr	His	Ser	Ser	Pro	Tyr				
		370				375					380								
His	Val	Ser	Asp	His	Lys	Ala	Ala	Val	Thr	Val	Gly	Val	Ile	Met	Gly				

385	390	395	400
Val Phe Leu Ile Cys Trp Val Pro Phe Phe Cys Val Asn Ile Thr Ala			
405		410	415
Ala Phe Cys Lys Ser Asp Arg Phe Ile Thr Asp Tyr Ala Ala Lys Asn			
420		425	430
Val Val Val Met Asn Ser Gly Arg Ser Ser Ala Glu Leu Glu Gln Val			
435	440		445
Ser Ala Ile			
450			

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 November 2001 (22.11.2001)

PCT

(10) International Publication Number
WO 01/87929 A3

(51) International Patent Classification⁷: **C12N 15/12**,
C07K 14/705, C12N 1/21, 5/10, C12Q 1/68, A61K 48/00,
C12N 15/62, G01N 33/68, A61K 31/7088, 39/395

(21) International Application Number: **PCT/EP01/05559**

(22) International Filing Date: **16 May 2001 (16.05.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/205,195 **18 May 2000 (18.05.2000) US**

(71) Applicant (for all designated States except US): **BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE).**

(72) Inventor; and

(75) Inventor/Applicant (for US only): **RAMAKRISHNAN, Shyam [IN/US]; 76 Euston Road, Apt. #10, Brighton, MA 02135 (US).**

(74) Common Representative: **BAYER AKTIENGESELLSCHAFT; 51368 Leverkusen (DE).**

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
30 May 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **REGULATION OF HUMAN DOPAMINE-LIKE G PROTEIN-COUPLED RECEPTOR**

(57) Abstract: Reagents which regulate human dopamine-like G protein-coupled receptor (DA-like GPCR) and reagents which bind to human DA-like GPCR gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, obesity and diseases related to obesity, cancer, diabetes, osteoporosis, anxiety, depression, hypertension, migraine, compulsive disorders, schizophrenia, autism, neurodegenerative disorders, such as Alzheimer's disease, Parkinsonism, and Huntington's chorea, and cancer chemotherapy-induced vomiting.

WO 01/87929 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/05559

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/705 C12N1/21 C12N5/10 C12Q1/68
A61K48/00 C12N15/62 G01N33/68 A61K31/7088 A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, SEQUENCE SEARCH, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 22131 A (ARENA PHARMACEUTICALS INC ;GORE MARTIN (US); LIAW CHEN W (US); LIN) 20 April 2000 (2000-04-20) sequences ID no.7 and no.8 page 23; table C page 13 -page 14; table B claims	1-9, 18-32
X	DATABASE EMBL 'Online! HS2013 accession number AL035423, 12 February 1999 (1999-02-12) A. PEARCE: "HUMAN DNA SEQUENCE FROM CLONE 2013 ON CHROMOSOME XQ25-26 CONTAINS A GENE FOR BRAIN MITOCHONDRIAL CARRIER PROTEIN-1 (BMCP1), ESTS, STSS, GSSS AND A CPG ISLAND" XP002166396 abstract	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

12 March 2002

Date of mailing of the international search report

27/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Le Cornec, N

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/05559

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 01 32864 A (MERCK PATENT GMBH ;DUECKER KLAUS (DE)) 10 May 2001 (2001-05-10) sequences ID no.1 and no.2 claims examples	1-12, 18-52
P,X	WO 00 31258 A (ARENA PHARMACEUTICALS INC ;LIAW CHEN W (US); LIN I LIN (US); CHEN) 2 June 2000 (2000-06-02) sequences ID no.7 and no.8 page 24, paragraph J -page 25, line 3; claims page 8, line 22 -page 16, line 2 page 26 -page 28, line 6; example 3 page 8, line 7 example 2	1-12, 18-32,45
P,X	WO 00 50562 A (SYNAPTIC PHARMA CORP) 31 August 2000 (2000-08-31) figures 1A-B,2A-B page 78, line 1 -page 85, line 8 claims	1-12, 15-70
P,X	EP 1 092 727 A (PFIZER LTD ;PFIZER (US)) 18 April 2001 (2001-04-18) the whole document especially sequences ID no.1 and no.2 page 31 claims	1-12, 15-70
E	WO 01 36473 A (PARODI LUIS A ;LIND PETER (SE); SEJLITZ TORSTEN (SE); SCHELLIN KAT) 25 May 2001 (2001-05-25) sequences ID no.1, no.73, no.2 and no.74 claims	1-12, 15-70
E	WO 01 42288 A (INCYTE GENOMICS INC ;REDDY ROOPA (US); AU YOUNG JANICE (US); BAUGH) 14 June 2001 (2001-06-14) sequences ID no.67 and no.28 page 94; table 3	1-12, 15-70

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 13-14, 71-75 completely and 15-17, 33, 55, 63, 65 partially

Claims 13 refers to a method of reducing the activity of a Dopamine-like GPCR using a reagent which specifically binds to the polynucleotide, claim 14 refers to a reagent that modulates the activity of a Dopamine-like GPCR polypeptide or polynucleotide and claim 15-17 refer to a pharmaceutical composition comprising the reagent and its use for modulating the activity of a dopamine-like GPCR in a disease without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported.

No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

claim 33 refers to a method of detecting a polypeptide using a reagent which specifically binds to the polypeptide and the search has been carried partially as far as the reagent "which specifically binds" is an antibody as claimed in claim 34.

Claim 55 refers to a method of reducing the activity of a human Dopamine-like GPCR protein by contacting a cell with a reagent which specifically binds to a product encoded by the polynucleotide of seq ID no.1. The search for claim 55 has been carried out partially as far as the reagent is an antibody, an antisense oligonucleotide or a ribozyme and the product is a polypeptide or a RNA as claimed in claims 56-59.

Claim 63 refers to a pharmaceutical composition comprising a reagent which specifically binds to a polypeptide of sequence ID no.2. The search for claim 63 has been carried out as far as the reagent is an antibody as claimed in claim 64.

Claim 65 refers to a pharmaceutical composition comprising a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence ID no.1. The search for claim 65 has been carried out as far as the reagent is a ribozyme or an antisense or an antibody as claimed in claims 66-68.

Claims 71-75 refer to a method of treating Dopamine-like GPCR disorder using a reagent that inhibits a function of a human Dopamine-like GPCR protein without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported.

No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 01/05559

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0022131	A	20-04-2000	AU 6299199 A	01-05-2000
			AU 6430799 A	01-05-2000
			EP 1137776 A2	04-10-2001
			EP 1121431 A1	08-08-2001
			ES 2163384 T1	01-02-2002
			WO 0021987 A2	20-04-2000
			WO 0022129 A1	20-04-2000
			WO 0022131 A2	20-04-2000
			AU 3790400 A	13-06-2000
			EP 1133559 A2	19-09-2001
			WO 0031258 A2	02-06-2000
WO 0132864	A	10-05-2001	WO 0132864 A2	10-05-2001
WO 0031258	A	02-06-2000	AU 3790400 A	13-06-2000
			EP 1137776 A2	04-10-2001
			EP 1133559 A2	19-09-2001
			WO 0031258 A2	02-06-2000
			WO 0022131 A2	20-04-2000
			AU 6299199 A	01-05-2000
WO 0050562	A	31-08-2000	US 6221660 B1	24-04-2001
			AU 3003500 A	14-09-2000
			EP 1075493 A2	14-02-2001
			WO 0050562 A2	31-08-2000
EP 1092727	A	18-04-2001	EP 1092727 A2	18-04-2001
			JP 2001186888 A	10-07-2001
WO 0136473	A	25-05-2001	AU 1617801 A	30-05-2001
			WO 0136473 A2	25-05-2001
WO 0142288	A	14-06-2001	AU 1956701 A	18-06-2001
			AU 2575601 A	18-06-2001
			WO 0142285 A2	14-06-2001
			WO 0142288 A2	14-06-2001